



Causes and consequences of inherited cone disorders



Susanne Roosing^{a, b, 1, 2}, Alberta A.H.J. Thiadens^{d, 2}, Carel B. Hoyng^{c, 2},
Caroline C.W. Klaver^{d, e, 2}, Anneke I. den Hollander^{a, b, c, 2}, Frans P.M. Cremers^{a, b, *, 2}

^a Department of Human Genetics, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

^b Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

^c Department of Ophthalmology, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

^d Department of Ophthalmology Erasmus Medical Centre, 3000 CA, Rotterdam, The Netherlands

^e Department of Epidemiology, Erasmus Medical Centre, 3000 CA, Rotterdam, The Netherlands

ARTICLE INFO

Article history:

Available online 22 May 2014

Keywords:

Cone disorder

Retina

Photoreceptors

Animal model

Therapy

ABSTRACT

Hereditary cone disorders (CDs) are characterized by defects of the cone photoreceptors or retinal pigment epithelium underlying the macula, and include achromatopsia (ACHM), cone dystrophy (COD), cone-rod dystrophy (CRD), color vision impairment, Stargardt disease (STGD) and other maculopathies. Forty-two genes have been implicated in non-syndromic inherited CDs. Mutations in the 5 genes implicated in ACHM explain ~93% of the cases. On the contrary, only 21% of CRDs (17 genes) and 25% of CODs (8 genes) have been elucidated. The fact that the large majority of COD and CRD-associated genes are yet to be discovered hints towards the existence of unknown cone-specific or cone-sensitive processes. The ACHM-associated genes encode proteins that fulfill crucial roles in the cone phototransduction cascade, which is the most frequently compromised (10 genes) process in CDs. Another 7 CD-associated proteins are required for transport processes towards or through the connecting cilium. The remaining CD-associated proteins are involved in cell membrane morphogenesis and maintenance, synaptic transduction, and the retinoid cycle. Further novel genes are likely to be identified in the near future by combining large-scale DNA sequencing and transcriptomics technologies. For 31 of 42 CD-associated genes, mammalian models are available, 14 of which have successfully been used for gene augmentation studies. However, gene augmentation for CDs should ideally be developed in large mammalian models with cone-rich areas, which are currently available for only 11 CD genes. Future research will aim to elucidate the remaining causative genes, identify the molecular mechanisms of CD, and develop novel therapies aimed at preventing vision loss in individuals with CD in the future.

© 2014 Elsevier Ltd. All rights reserved.

Contents

1. Introduction	2
2. Phenotypic and genetic characteristics of cone disorders	2
2.1. Clinical methods	3
2.2. Clinical and genetic characteristics of non-syndromic cone disorders	3
2.2.1. Achromatopsia	3
2.2.2. Cone dystrophy	3
2.2.3. Cone-rod dystrophy	3
2.2.4. Color vision impairment	6
2.2.5. Maculopathies	7

* Corresponding author. Department of Human Genetics, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Tel.: +31 24 36 13750; fax: +31 24 36 68752.

E-mail address: Frans.Cremers@radboudumc.nl (F.P. Cremers).

¹ Current address: Howard Hughes Medical Institute, University of California, San Diego, La Jolla, CA 92093, USA.

² Percentage of work contributed by each author in the production of the manuscript is as follows: Susanne Roosing: 30%; Alberta A.H.J. Thiadens: 15%; Carel B. Hoyng: 10%; Caroline C.W. Klaver: 10%; Anneke I. den Hollander: 10%; Frans P.M. Cremers: 25%.

<http://dx.doi.org/10.1016/j.preteyeres.2014.05.001>

1350-9462/© 2014 Elsevier Ltd. All rights reserved.

2.2.6. Other maculopathies	7
2.3. Clinical and genetic characteristics of syndromic cone disorders	9
2.4. Differential diagnosis	9
3. Cone disorder mechanisms	9
3.1. Phototransduction cascade	9
3.2. Retinoid cycles	12
3.3. Photoreceptor development and structure	12
3.4. Transport processes	13
3.5. Synaptic transduction	13
3.6. Miscellaneous	14
4. Mammalian models for cone disorders	14
4.1. Mouse models for cone disorders	14
4.2. Other animal models of cone disorders	16
5. Therapeutics for cone disorders	16
6. Future perspectives	17
6.1. Identification of CD-associated genes	17
6.2. Molecular diagnostics	17
6.3. Transcriptomics	18
6.4. Alternative cone rescue strategies	18
7. Conclusions	18
Acknowledgments	18
Supplementary data	18
References	18

1. Introduction

Cone disorders (CDs) are a group of inherited diseases of the cone, or cone and rod photoreceptors, or retinal pigment epithelium (RPE), that are associated with various forms of stationary or progressive visual impairment. Linkage analysis, homozygosity mapping, and more recently whole exome sequencing (WES), facilitated the identification of genes mutated in patients with CDs such as achromatopsia (ACHM), cone dystrophy (COD), cone-rod dystrophy (CRD), and other cone-related disorders. CDs can follow all modes of Mendelian inheritance, i.e. autosomal recessive (AR), autosomal dominant (AD) and X-linked (XL), and can present as non-syndromic and syndromic forms. Thus far, reviews were focused on stationary cone disorders (Michaelides et al., 2004b) as well as the genetic spectrum of cone disorders (Berger et al., 2010). Here, we provide an overview of the expanded genetic repertoire of inherited cone disorders and novel genotype–phenotype correlations. Despite the high clinical and genetic heterogeneity of CDs the genetic defects underlying 21–93% of certain subsets of the cases have been identified. The proteins encoded by CD-associated genes are involved in a variety of processes, including the cone phototransduction cascade, visual cycles, photoreceptor development, ciliary transport, disk membrane morphogenesis and synaptic transport. Studies in mammalian models show that gene replacement therapies, due to the accessibility and immune-privileged nature of the eye, provide an opportunity to correct the visual impairment. In this review we present a comprehensive overview of the genes and associated disease mechanisms of non-syndromic CDs, touch upon the genetic causes of syndromic CDs, and evaluate therapeutic strategies aiming to prevent vision loss in CD in the future.

2. Phenotypic and genetic characteristics of cone disorders

Hereditary CDs constitute a large clinically heterogeneous group of diseases in which the cone photoreceptors or RPE are primarily affected. Cone photoreceptor cells account for only 5% of the total number of photoreceptors, the other 95% consisting of rods. In humans, the retina contains 3–6 million cone photoreceptors

concentrated in the fovea enabling detailed vision, spatial resolution, reading, facial recognition and color vision. These important cone functions explain why CDs have such a disabling impact on the daily living tasks of those affected, further compounded by the early onset of disease and severe visual outcome of many of these disorders.

We analyzed all publicly available literature on CDs and, to estimate the contribution of specific genes, only included studies with clearly defined patient cohorts (Supplementary Tables 1–5). Using this approach, we estimated that AR/isolated (I) CDs are found in 76.7% of cases, AD inheritance in 21.6% of cases and X-linked inheritance in the remaining 1.4% (Fig. 1). In this chapter we




Fig. 1. Frequency of clinical subtypes and inheritance patterns of genetically heterogeneous cone disorders. Estimate of the frequencies of clinical subtypes and modes of inheritance of the genetically heterogeneous forms of CD, i.e. achromatopsia (ACHM), which invariably is inherited in an AR manner, cone dystrophy (COD), and cone-rod dystrophy (CRD). The majority of the AR COD and AR CRD cases are isolated (I) cases in which a recessive mode of inheritance is most likely. In most studies in which AD forms of COD and CRD were analyzed, no clear distinction was made between these disease entities, and therefore they are grouped together.

provide an overview of the clinical and genetic characteristics of different forms of non-syndromic and syndromic CDs.

2.1. Clinical methods

Ophthalmic examination and diagnostic testing is essential to differentiate cone-rod from rod-cone (i.e. RP) disorders. Although a number of tests are helpful in the diagnostic process, color vision testing of all three color axes such as Hardy Rand and Rittler tests, full-field ERG, and Goldmann perimetry, have been proven to be the most useful (Thiadens et al., 2013). With SD-OCT the morphology of the cone photoreceptor cells can be visualized. A single-section scan to obtain a longitudinal section across the center of the macula, and a volume scan should be performed to ensure capturing the center of the fovea. Retinal thickness measurements in the fovea including the outer nuclear layer, inner and outer segments of the cone cells, and RPE. For future gene therapy purposes, SD-OCT can be considered as a useful diagnostic tool for visualizing the severity of cone photoreceptor loss.

In Table 1, we summarized the ophthalmic symptoms and characteristics for ACHM, oligocone trichromacy (OT), blue cone monochromatism (BCM), COD, CRD and Stargardt disease (STGD). Further details of these and other CDs can be found below.

2.2. Clinical and genetic characteristics of non-syndromic cone disorders

2.2.1. Achromatopsia

Patients with ACHM (Fig. 2A and B, Table 1) present shortly after birth with significantly reduced visual acuity, severe photophobia, a congenital pendular nystagmus, and color vision defects in the protan, deutan and tritan color axes. High refractive errors are common in these patients. The macula can have a variable appearance ranging from no abnormalities to atrophic lesions. Full-field electroretinography (ERG) demonstrates absent or residual cone responses with normal rod responses (Kohl et al., 2000; Thiadens et al., 2009b). The first signs of pathology on SD-OCT are loss of inner- and outer cone segments with disruption of the ciliary layer, which may be followed by the appearance of an optical empty cavity with cell loss in the cone photoreceptor layer, at least in some studies. The end stage is generally characterized by a complete loss of photoreceptors and atrophy of the RPE in the fovea (Genead et al., 2011; Sundaram et al., 2014). For future gene therapy purposes, SD-OCT can be considered as a useful diagnostic tool for visualizing the severity of cone photoreceptor loss.

The estimated prevalence of ACHM is 1:40,000 individuals and it is exclusively inherited in an AR manner. The genetic etiology of ACHM has been almost completely unraveled. Mutations in the five genes associated with ACHM (Fig. 3A) explain 93% of cases in the Caucasian population. All causal genes encode essential proteins in the cone phototransduction cascade (see paragraph 3) (Kohl et al., 2000; Thiadens et al., 2009b). Importantly, the limited number of genes involved in ACHM renders this disease a suitable candidate for future gene-based therapies. Nevertheless these therapies can only succeed if viable cone photoreceptor cells are still present in the retina (Carvalho et al., 2011; Komáromy et al., 2010; Michalakos et al., 2010; Pang et al., 2010).

2.2.2. Cone dystrophy

Patients with cone dystrophy (COD, Fig. 2C and D, Table 1) have normal cone function initially, but present with loss of visual acuity and color vision disturbances in the first or second decades of life. Complaints of photophobia or hemeralopia may also exist. In X-linked (XL) COD cases with a mutation in the ORF15 region of *RPGR*, hemeralopia has been reported as a first symptom preceding visual

loss in more than a quarter of the patients (Thiadens et al., 2012a). These *RPGR*-associated COD patients typically have high myopic refractive errors of more than 6 diopters (Thiadens et al., 2012a). Because the cone function is initially normal in COD, nystagmus is usually not observed. Macular abnormalities may be present ranging from no abnormalities to a bull's eye maculopathy or RPE atrophy. The optic nerve may have variable degrees of temporal pallor. Goldmann perimetry shows a reduced central sensitivity or (relative) scotoma with intact peripheral visual fields (Michaelides et al., 2006). Color vision is generally affected in all three axes. Reduced cone responses with preserved rod responses on ERG are an important clinical hallmark for the diagnosis of COD, although the vast majority of patients with COD develop rod involvement over time complicating the diagnosis. The mean onset of disease is at adolescence but the course of the disease may vary. Visual acuity generally worsens to legal blindness before 50 years of age (Thiadens et al., 2012a).

COD has an estimated prevalence of 1:30,000–40,000 (Michaelides et al., 2004b). Although all Mendelian inheritance patterns have been reported the AR form is by far the most common. The genetic causes of the autosomal dominant (AD) and XL forms have been solved to a large extent, but 75% of AR forms remain to be elucidated (see Fig. 3B). This is remarkable and hints towards the existence of completely unknown and uncharacterized cone-specific or cone-sensitive processes. Some of the genes associated with AR forms have a characteristic phenotypic appearance, like COD patients with mutations in the *KCNV2* gene. Mutations in this gene show supra-normal rod responses on ERG. Besides these remarkable ERG findings, most young patients also have a relatively late onset in loss of visual acuity (Zelinger et al., 2013). The rod responses on ERG do not appear to coincide with a gain of rod visual acuity, on the contrary, studies showed loss of acuity for rod as well as cone cells in patients carrying *KCNV2* mutations (Robson et al., 2010; Stockman et al., 2014; Zelinger et al., 2013). The clinical course of *ABCA4*-associated COD has also been studied in detail. This gene encodes a transmembrane protein located in rod and cone outer segments. AR-COD patients with mutations in this gene show an earlier onset, a rapid decline of visual acuity, and a significantly worse visual outcome than patients without *ABCA4* mutations (Thiadens et al., 2012a).

2.2.3. Cone-rod dystrophy

Cone-rod dystrophy (CRD, Fig. 2E and F, Table 1) can be distinguished from COD by early rod involvement or concomitant loss of both cones and rods on ERG. Symptoms resemble those of COD, with complaints of loss of visual acuity and central vision, sometimes photophobia, and color vision disturbances. However, patients may also experience nyctalopia due to rod degeneration. With an onset in childhood and a rapid decline of the visual function to legal blindness before the age of 40, the course of CRD seems more severe than for COD (Thiadens et al., 2012a). The macular appearance resembles that of COD, but patients may also develop retinal vascular attenuation and peripheral pigment deposits. Visual fields show a (relative) central scotoma with variable degrees of peripheral involvement. CRD is usually non-syndromic but it can manifest as part of a syndrome (see 2.3).

As in COD the prevalence of CRD is 1:30,000–40,000 and can be inherited in an AR, AD or XL manner (Hamel, 2007). Currently, 17 genes and some additional loci are known to be involved in AR CRD explaining approximately 22% of the cases (Fig. 3C). As COD and CRD cases often are difficult to distinguish clinically, we have combined genetic data from the autosomal dominant forms of COD and CRD. In AD COD/CRD 21% of the cases were solved (Fig. 3D) and in XL COD/CRD 74% (Fig. 3E).

Table 1
Clinical characteristics to differentiate the major inherited cone disorders.

	ACHM	OT	BCM	COD	CRD	STGD
Vision	0.05–0.20	0.05–0.40	~0.10	0.05–0.40	0.05–0.40	0.1–0.5
Nystagmus	+	±	+	–	–	–
Color vision	Disturbed in protan/deutan/tritan color axes	Not disturbed	Disturbed in protan and deutan color axes	Disturbed in protan/deutan/tritan color axes	Disturbed in protan/deutan/tritan color axes	Disturbed in protan/deutan color axes
Photophobia	+	±	+	±	±	±
Hemeralopia	–	–	–	±	±	–
Nyctalopia	–	–	–	–	±	–
Hypermetropia >+2D	+, ~30%	?	–	–	–	–
Myopia <–2D	+, ~25%	?	+	+, ~20% even more than >–6D	+, ~20% even more than >–6D	–
Retinal appearance	Normal to bull's eye/atrophic macular lesions	Normal to bull's eye/atrophic macular lesions	Normal to macular atrophy and RPE atrophy	Normal to bull's eye/atrophic macular lesions, temporal pallor of optic disc	Normal to bull's eye/atrophic lesions, peripheral RPE atrophy, vascular attenuation	Bull's eye, mostly surrounded by flecks. In rare cases flecks spread up to the arcades
SD-OCT	Normal- absence of central cone PRL	Thinner central retina, no absence of cone PRL	Absence of central cone PRL	Normal-absence of central cone PRL	Normal-absence of central cone PRL, central retinal thinning	Thinning or absence of central cone PRL
FAF	Normal to absent FAF in the macula	ND	Normal to absent FAF in the macula	Normal to absent FAF in the macula	Normal to absent FAF in the macula	70% dark choroid
Goldmann perimetry	Reduced central sensitivity to (relative) central scotoma	Reduced central sensitivity	Reduced central sensitivity to (relative) central scotoma	Reduced central sensitivity to (relative) central scotoma	Reduced central sensitivity to (relative) central scotoma, with variable peripheral involvement	Reduced central sensitivity
mfERG	Reduced/non detectable macular responses	Reduced/non detectable macular responses	Reduced/non detectable macular responses	Reduced/non detectable macular responses	Reduced/non detectable macular responses	Reduced
ffERG	Reduced/absent cone responses. Normal rod responses	Normal to slightly reduced cone responses. Normal rod responses	Reduced/absent cone responses with a preservation of the blue cones	Reduced/absent cone responses. Initial normal rod responses	Cone responses are absent or more severely reduced than rod responses	Reduced cone responses

+, Present; –, absent; ACHM, achromatopsia; AD, autosomal dominant; AR, autosomal recessive; BCM, blue cone monochromatism; COD, cone dystrophy; CRD, cone-rod dystrophy; D, Diopters; FAF, fundus autofluorescence; ffERG, full-field electroretinogram; mfERG, multifocal electroretinogram; NA, not analyzed; ND, not described; OT, oligocone trichromacy; PRL, photoreceptor layer; SD-OCT, spectral domain-optical coherence tomography; STGD, Stargardt disease; XL, X-linked.




Fig. 2. Fundus and autofluorescence images of cone disorders and other maculopathies. Fundus and autofluorescence images of patients with a cone disorder (CD), in order of description in the article from left to right and up and down (A–R). A/B) Achromatopsia. A) The central macula shows mottling of the RPE, which corresponds with B) the small region of absent fundus autofluorescence (FAF) in the center due to the RPE alterations. C/D) Cone dystrophy. C) The optic disc shows temporal pallor of the optic disc; the macula presents with a bull's eye maculopathy with mottling of the RPE (color photograph). D) The fovea shows a small central region with absent FAF caused by RPE atrophy, surrounded by discrete hyperfluorescent lesions (FAF image). E/F) Cone-rod dystrophy. E) The central macula shows an area of diffuse RPE degeneration (color photograph). F) The lesion corresponds to absence of FAF in the center, surrounded by a discrete lesion of higher FAF intensity (FAF image). G/H) Stargardt disease. G) The posterior pole shows multiple yellow fish-tailed flecks, some pigment clumping, and bull's eye maculopathy with RPE atrophy (color photograph). H) The central macula shows decreased FAF, whereas the flecks exhibit increased FAF on a background of irregular FAF (FAF image). I/J) Best vitelliform macula dystrophy. I) The macula has an egg-yolk appearance corresponding to the vitelliform stage of Best (color photograph). J) The FAF of the lesion is intensely increased (FAF image). K/L) Central areolar choroidal dystrophy. K) In the macula a sharply demarcated lesion with RPE atrophy is visible, surrounded by a few small round white lesions (color photograph). L) The atrophic area causes a decreased FAF bordered by a small band of increased FAF (FAF image). M/N) Butterfly-shaped macular dystrophy. M) The macula shows an irregular yellow pigmented lesion with some RPE degeneration (color photograph). N) The central area has decreased FAF while the yellow pigment show increased FAF resembling a 'pattern' (FAF image). O/P) Adult-onset foveomacular vitelliform dystrophy. O) The macula reveals an oval yellow subfoveal lesion with central pigment (color photograph). P) The lesion shows an intensely increased FAF; the border of the lesion shows a band of decreased FAF (FAF image). Q/R) Cystoid macular dystrophy. Q) The macula shows focal thickening of the retina in the center (color photograph). R) The pooling of fluid in the macula gives a classical flower-petal pattern of FAF (FAF image).




Fig. 3. Frequency and genetic causes of cone disorders. Estimates of the current frequency and genetic causes in cone disorders (CD). We only assessed studies in which cohort sizes were clearly indicated. A) ACHM. Mutations in five genes explain 93% of the cases, with the largest contribution by *CNGB3*, followed by *CNGA3*. For the included studies see Supplemental Table 1. B) Autosomal recessive and isolated COD. Eight genes each are mutated in a small proportion of the cases and together form the basis of disease in 25% of the cases. For the included studies see supplemental Table 2; DNA samples in the study of Littink et al. (2010) have been scanned using homozygosity mapping (no Sanger sequencing) and therefore have been excluded from numerical analysis. C) Autosomal recessive and isolated CRD. Seventeen genes are implicated in AR/I CRD, together responsible for 23% of the cases, of which only *ABCA4* is mutated in a significant proportion. For the included studies see supplemental Table 3. D) Autosomal dominant COD and CRD. Ten genes are mutated in these conditions, mutations in which explain not more than 20% of the cases. For the included studies see Supplemental Table 4, and E) X-linked COD and CRD. For the included studies see Supplemental Table 5.

Mutations in the *ABCA4* gene are not only implicated in Stargardt disease, but also the most prevalent cause of AR CRD. However its involvement varies widely between studies. In the Caucasian population this percentage varies between 26 and 65% (Maugeri et al., 2000; Thiadens et al., 2012a); in a recent Chinese study only 1/47 cases carried *ABCA4* variants. This also suggests a much lower prevalence of Stargardt disease (STGD1) in this population as previously suggested (Baum et al., 2003; Huang et al., 2013). In CRD patients with two pathogenic *ABCA4* variants, the observed visual prognosis is significantly worse than in patients with mutations in other genes, with a mean age of legal blindness more than 20 years earlier (Thiadens et al., 2012a).

One study suggested that *CNGB3* (3/47) and *PDE6C* (2/47) are involved in CRD (Huang et al., 2013), while previous studies only identified *CNGB3* and *PDE6C* mutations in COD. Reasons for this discrepancy could include different genetic backgrounds, or incomplete phenotyping.

2.2.4. Color vision impairment

Normal human color vision is mediated by three types of cone photoreceptors that are maximally sensitive to light at 565 nm (the red cones, long [L] wavelength sensitive), at 535 nm (the green cones, middle [M] wavelength sensitive), and at 440 nm (the blue cones, short [S] wavelength sensitive). The rods are maximally sensitive to light at 500 nm, mediate vision in dim light, and contribute little to color sense. Humans thereby generally have trichromatic color perception. The most frequent

form of color vision impairment is dichromacy, which is observed in ~6% of males and 0.4% of females. Dichromats have lost one class of pigment, either the L, M or S pigments, and are named protanopes, deuteranopes, and tritanopes, respectively, the latter of which are very rare. The more frequent protanopes and deuteranopes carry deletions of the red (*OPN1LW*) or green (*OPN1MW*) pigment genes, nonsense mutations in these genes, or missense mutations that influence their spectral tuning (Gardner et al., 2010, 2012).

Persons with X-linked blue cone monochromatism (XL-BCM) have a similar clinical presentation as those with ACHM with photophobia, nystagmus, severe color vision disturbances, and a low visual acuity of ~0.10 in early childhood (Table 1) (Gardner et al., 2009). To distinguish BCM from ACHM it is necessary to use color vision tests that specifically select for the blue color axis such as Berson plates (Berson et al., 1983). Color ERGs may also distinguish between responses from different cone types and may detect signals from intact blue cones on a background of absent signals from red and green cones (Scholl and Kremers, 2003). XL-BCM is very rare with a prevalence of 1:100,000 individuals (Michaelides et al., 2004b). The red and green cone opsins are absent which in almost 40% of BCM can be explained by deletions in the locus control region, the region regulating transcription of the red and green opsin genes (Nathans et al., 1989; Gardner et al., 2009). Other BCM patients carry a p.Cys203Arg variant in a single green or red–green hybrid gene that remained after non-homologous recombination (Nathans et al., 1989). Together with a cysteine at

amino acid position 126, this cysteine forms a conserved disulfide bond that is important for protein stability.

Bornholm eye disease is an XL disease that has been reported in a large Danish family originating from the Danish island of Bornholm, characterized by a low visual acuity, a reduced photopic ERG, moderate to high myopia, and deuteranopia. Linkage analysis mapped the defect to a chromosomal region encompassing the red and green opsin gene array, suggesting overlap with congenital color blindness (deuteranopia). Recently, families with Bornholm eye disease, that display dichromacy and myopia, were shown to carry sequence variants in the first *OPN1LW* gene copy, which presumably lowers the amount of functional protein (McClements et al., 2013; Michaelides et al., 2005b; Ueyama et al., 2012).

Oligocone trichromacy (OT) is a rare condition first described in 1973 by van Lith (van Lith, 1973). It is characterized by reduced visual acuity, mild photophobia, nearly normal color vision, a normal fundus appearance, and reduced cone responses with normal rod responses on multifocal ERG (Table 1). It has been proposed that these patients have a reduced number of central cones or a reduced number in total number of cones (oligocone). The disease has an AR inheritance, and genetically there is considerable overlap with ACHM, as mutations in *CNGA3*, *CNGB3* and *GNAT2* have been associated with this form of CD (Michaelides et al., 2004a; Vincent et al., 2011).

2.2.5. Maculopathies

Autosomal recessive Stargardt disease (STGD1, Fig. 2G and H, Table 1) is the most prevalent inherited AR juvenile retinal dystrophy, with an estimated frequency of ~1:10,000 (Blacharski, 1988). Fundus flavimaculatus is a largely overlapping phenotype with a later onset, slower progression, and more widespread distribution of flecks (Franceschetti, 1963; Noble and Carr, 1979; Stargardt, 1909). Hereafter, fundus flavimaculatus will not be mentioned separately. STGD1 can arise in the first decade, but can also have an onset much later in life (up to 70 years of age). The outcome is generally poor central vision developing only a few years after the age of onset, but the prognosis may be better due to foveal sparing in some cases (Rotenstreich et al., 2003; Westeneng-van Haften et al., 2012; Yatsenko et al., 2001). STGD1 patients show a dark choroid in ~80% of the cases upon fluorescein angiography due to the lipofuscin accumulation, which prevents the background fluorescence of the choroid (Armstrong et al., 1998; Fishman et al., 1999).

A combination of a mild and a severe, or two moderately severe mutations in *ABCA4* gives rise to STGD1 (Allikmets et al., 1997; Maugeri et al., 1999), whereas the combination of two severe mutations in *ABCA4* are known to cause panretinal, severe CRD which, at the end stage, may be difficult to discriminate from typical retinitis pigmentosa (RP) (Cremers et al., 1998). The estimated carrier frequency of *ABCA4* variants in the normal population can be as high as 1:20 (Maugeri et al., 1999). As described in more detail in paragraph 3.2, a deficiency of *ABCA4* results in accumulation of lipofuscin in the RPE which can be seen in and around the macula as yellowish white flecks. In animals as well as in patients, it was shown that a defective *ABCA4* protein causes accumulation of N-retinylidene-PE in the RPE, which forms a potential toxic component inducing photoreceptor death (Mata et al., 2000; Weng et al., 1999).

In persons with CRD and *ABCA4* mutations there appears to be an intrinsic and severe defect in photoreceptors, which directly leads to photoreceptor loss and lipid accumulations in the RPE are mostly absent.

2.2.6. Other maculopathies

Mutations in *PRPH2* have been associated with AD central areolar choroidal dystrophy (CACD, Fig. 2K and L), “pseudo-

Stargardt pattern dystrophy” (Boon et al., 2007), pattern dystrophies like butterfly-shaped pigment dystrophy (BSMD, Fig. 2M and N) and adult-onset foveomacular vitelliform dystrophy (Fig. 2O and P), as well as AD retinitis pigmentosa (Boon et al., 2008). The *PRPH2* protein product RDS/peripherin is a photoreceptor-specific glycoprotein crucial in photoreceptor outer segment discs development and maintenance (Fig. 4, left lower panel) (Arikawa et al., 1992; Connell et al., 1991; Travis et al., 1991). It has been hypothesized that abnormal RDS/peripherin protein results in an altered cone outer segment structure and potentially an altered rod outer segment structure (Boon et al., 2009a). This may interfere with the photoreceptor outer segment-RPE interaction leading to accumulation of lipofuscin and byproducts in the RPE cells resulting in apoptotic cell death of RPE and photoreceptor cells. Pattern dystrophies due to *PRPH2* mutations are presumed to arise by disruption of the photoreceptor disc membranes (Wickham et al., 2009; Zhang et al., 2002a).

Best vitelliform macular dystrophy (BVMD, Fig. 2I and J), a member of the group of “bestrophinopathies”, is caused by AD inherited mutations in the *BEST1* (or *VMD2*) gene, which encodes the bestrophin-1 protein, a calcium-activated chloride channel located at the baso-lateral membrane of RPE cells, that also influences voltage-gated calcium channels within the RPE. Furthermore, *BEST1* localized mostly to the ER close to the baso-lateral plasma membrane and is involved in the storage-dependent Ca-influx into RPE cells (Gomez et al., 2013). The age at onset of central vision loss is highly variable ranging from the first to the sixth decade (Clemett, 1991; Wabbers et al., 2006). The disease-course of BVMD begins with the asymptomatic carrier (“pre-vitelliform”) stage, progressing to variable clumping of vitelliform material in the vitelliruptive or “scrambled-egg” stage, culminating in variable degrees of chorioretinal atrophy and subretinal scarring in the cicatricial stage. Patients with AR bestrophinopathy have more extensive retinal abnormalities and carry a *BEST1* mutation on both alleles (Burgess et al., 2008). Hypothetically, causes of RPE dysfunction in BVMD are related to abnormal ionic transport leading to the accumulation of subretinal fluid and vitelliform material originating from photoreceptor outer segment-waste products and lipofuscin loaded pigmented cells (Boon et al., 2009b). The overload of the RPE eventually leads to photoreceptor and RPE dysfunction.

PRPH2 variants have also been associated with BVMD and like *BEST1* mutations, are also associated with a high phenotypic heterogeneity and limited genotype–phenotype correlation (Boon et al., 2008, 2009b).

Genes with a minor contribution to AD macular dystrophies are *C1QTNF5*, *EFEMP1*, *FSCN2*, *GUCA1B*, *HMCN1*, *IMPG1*, *RP1L1* and *TIMP3*. Three of these present a rare but particular phenotype; *EFEMP1* mutations are a cause of AD Doyme honeycomb retinal degeneration (Malattia Leventinese) (Stone et al., 1999) which presents with drusen deposits at the level of Bruch's membrane in the macula around the edge of the optic nerve head (Gregory et al., 1996). Occult macular degeneration is caused by heterozygous mutations in *RP1L1* and is involved in central cone dysfunction and vision loss with a normal appearing retina (Akahori et al., 2010). Sorsby's fundus dystrophy develops due to mutations in *TIMP3* and is recognized by loss of central vision from subretinal neovascularization, as well as atrophy of the choriocapillaris, RPE and retina (Weber et al., 1994).

For seven other AD macular conditions, the underlying genetic causes are not yet known. Autosomal dominant macular dystrophy with cystoid macular edema (dominant cystoid macular dystrophy, DCMD; a.k.a. cystoid macular dystrophy, CYMD, Fig. 2Q and R) causes visual acuity loss in the second decade of life with or without strabismus (Deutman et al., 1976). As the disease progresses, the




Fig. 4. Schematic representation of the roles of the non-syndromic cone disorder-associated proteins in the human retina. Schematic representation of five major functionalities of human cone photoreceptor cells (PC), Müller cells and the RPE. The locations and functions of proteins involved in non-syndromic CD are depicted in different colors. Proteins which are relevant for the different cellular processes and not mutated in CD are given in black lettering. Some CD-associated proteins are not shown in this figure either because of their wide-spread localization in the retina (EFEMP1, FSCN2, HMCN1), or because they localize to structures not shown (TIMP3). Left upper panel) The retinoid cycle taking place in cone photoreceptor cells and the RPE. Upon photoactivation (indicated by a lightning symbol), 11-cis-retinal is converted into all-trans-retinal and dissociates from activated cone opsins, OPN1LW and OPN1MW (activated opsins indicated by an asterisk). All-trans-retinal is then recycled to 11-cis-retinal via several enzymatic steps in the RPE. Transport of all-trans-retinal is mediated by ABCA4. Left middle panel) Retinoid cycle in cones and Müller cells. Upon photoactivation, isomerization of 11-cis to all-trans-retinal in a cone opsin takes place. After dissociation, all-trans-retinal is reduced to all-trans-retinol by RDH8 and then released from the cone outer segment into the interphotoreceptor matrix where it is bound by IRBP and taken up by the Müller cells. All-trans-retinol is isomerized by dihydroceramide desaturase-1 (DES1) to 11-cis-retinol, 9-cis-retinol and 13-cis-retinol, of which 11-cis-retinol is subsequently bound to cellular retinal-binding protein (CRALBP). The interphotoreceptor retinoid-binding protein (IRBP) transports 11-cis-retinol to the cone outer segments. 9-cis-retinol diffuses directly to the interphotoreceptor matrix and into cone outer segments, and together with 11-cis-retinol is oxidized by an unknown retinol dehydrogenase to 9/11-cis-retinal which subsequently is combined with apo-opsin to form a new chromophore. Left lower panel) Developmental and structural proteins. Three transcription factors mutated in non-syndromic CD are CRX, NR2E3 and RAX2. Other proteins important in the morphogenesis and structure of the cone photoreceptor cell are EYS, IMPG1, PRPH2, PROM1, and PCDH21. Right upper panel) The phototransduction cascade in cone photoreceptor cells. Upon activation, amplification of the signal is mediated by the α -subunit of transducin and the α' - and γ -subunits of cone phosphodiesterase, encoded by *PDE6C* and *PDE6H*. This results in closure of the cGMP-gated channel composed of CNGA3 and CNGB3, a hyperpolarization of the cell and a reduction in glutamate release at the synaptic region. The *KCNV2* gene encodes a voltage-gated potassium channel subunit together with other channel components and regulated the potassium current in the cell and affects its excitability potential. PDE6 and transducin subunits are marked as alpha (α), alpha' (α'), beta (β), and gamma (γ). Right lower panel) CD-associated proteins involved in transport processes in the cone photoreceptor cell. AIPL1 is a chaperone of the putative farnesylated protein PDE6C. Farnesylated proteins are marked with a red zig-zag icon. C8orf37, RAB28, RIMS1, and TULP1, based on immunolocalisation studies act predominantly in transport processes toward and at the base of the connecting cilium, whereas RPGR and RRGRI1 act throughout the connecting cilium. UNC119 is responsible for ciliary delivery of myristoylated proteins as well as the dissociation of transducin in separate subunits in mice. ATP, adenosine-triphosphate; GTP, guanosine-5'-triphosphate; GDP, guanosine diphosphate; GMP, guanosine monophosphate; cGMP, cyclic GMP; IRBP, interphotoreceptor retinoid binding protein, the product of *RBP3*; MII, metarhodopsin II; P, phosphorylation; RAL, retinal; RE, retinyl esters; REH, retinyl ester hydrolase; ROL, retinol.

macula will develop a central zone of “beaten bronze” atrophy. The DCMD locus was positioned to an approximately 20-cM region between markers D7S493 and D7S526 on chromosome 7p15-p21 (Kremer et al., 1994), but the gene has remained elusive.

North Carolina macular dystrophy (NCMD) is an AD macular dystrophy with an early childhood onset and a stable course (Lefler et al., 1971; Schworm et al., 1998; Small et al., 1991). The highly

variable phenotype contains yellow drusen-like lesions with retinal pigmentary changes of variable severity (Small, 1989; Small et al., 1991). The corresponding locus, MCDR1, was identified on chromosome 6q16 (Small et al., 1992; Yang et al., 2008), but the gene and its presumed function are currently unknown. Benign concentric annular macular dystrophy (BCAMD) is described in a Dutch family and may be caused by a mutation in *IMPG1* (van Lith-

Verhoeven et al., 2004). An early-onset AD macular dystrophy (MCDR3) resembling NCMD has been mapped to chromosome 5 (Michaelides et al., 2003; Rosenberg et al., 2010). The defect in a Greek family with macular dystrophy has been positioned on chromosome 19q (MCDR5) (Yang et al., 2006).

2.3. Clinical and genetic characteristics of syndromic cone disorders

In a minority of cases, cone-rod disorders are not limited to a degeneration of the retina, but show systemic involvement as well. Ocular signs and symptoms may precede or follow the onset of systemic features and it is therefore recommended to incorporate a comprehensive ophthalmologic examination into the regular clinical work-up of patients with additional non-ocular features.

CD can be part of a syndrome or complex disease like Danon disease, Alström syndrome, or Jalili syndrome. Danon is a rare genetic condition caused by mutations in the X-linked lysosome-associated membrane protein gene (*LAMP2*), and consists of the triad muscle weakness, cardiomyopathy, and mental impairment. The mortality rate in males is high; the most frequent cause of death is a heart arrhythmia. Female carriers can show a milder phenotype, often restricted to cardiomyopathy (Maron et al., 2009). Ophthalmic involvement has been reported in several cases, varying from macular abnormalities to CRD (Prall et al., 2006; Thiadens et al., 2012b). In one family, with a missense mutation in *LAMP2*, affected males presented with all features of CRD. The onset in this family was relatively late (middle-age) and visual acuity declined to legal blindness within two decades thereafter (Thiadens et al., 2012b).

Another example is the very rare AR Alström syndrome. It is characterized by CRD, hearing loss, obesity, diabetes, short stature, cardiomyopathy, and a progressively failure of lungs, liver and kidney. The disease manifests in early childhood and leads to a reduced life expectancy. Age of onset, severity of symptoms and prognosis may vary depending on genetic background. Alström syndrome is caused by mutations in the *ALMS1* gene, which codes for a ciliary protein present in basal bodies, centrosomes and cytosol of the cells. Patients with Alström disease present with a low visual acuity, nystagmus and photophobia on occasion, atrophic lesions of the retina, and an abnormal cone-rod ERG. Phenotypically this ciliopathy shows similarities to Bardet-Biedl syndrome (Marshall et al., 2011).

Jalili syndrome (cone dystrophy with amelogenesis imperfecta) is caused by autosomal recessive mutations in *CNNM4*, encoding a metal transporter protein. Patients present with a demineralization of both primary and secondary dentition with or without COD. A large Arab family with Jalili syndrome showed low visual acuity since early childhood, photophobia and nystagmus in some cases, absent color vision, and a bull's eye maculopathy or atrophic macular degeneration. Cone responses were more reduced than rod responses (Jalili, 2010), consistent with a retinal diagnosis of COD.

A novel syndrome of North Carolina-like macular dystrophy with progressive sensorineural hearing loss (MCDR4) was linked to chromosome 14q (Francis et al., 2003).

2.4. Differential diagnosis

CDs form a genetically complex disease spectrum with a large phenotypic variability. Different mutations can result in similar phenotypes, whereas many genetic factors may contribute to the phenotypic variability of one causative mutation. Traditionally, Leber congenital amaurosis (LCA) has been considered as the congenital form of retinal dystrophy and it is typically associated with a very low vision at birth accompanied by roving nystagmus,

amaurotic pupils, and a high hypermetropic refractive error. Visual acuity ranges from 0.10 Snellen visual acuity to no light perception. Eye poking (oculodigital reflex) can be observed in young children. Most often no fundus abnormalities are present, but in later stages round subretinal pigment clumps or bone-spicule-like pigment changes can develop. ERG responses are undetectable for both rods and cones before the age of one year. With an inconclusive ERG result, it is sometimes necessary to repeat the ERG after the age of 1 year to obtain the correct diagnosis. The prevalence of LCA varies from 1:30,000 to 1: 81,000 (Koenekoop, 2004; Stone, 2007). In most cases the inheritance modus is AR, but cases of AD inheritance have been described. Systemic disorders that are associated with LCA or a LCA-like ocular phenotype are Alström syndrome (Alström et al., 1959), Batten disease (Steinfeld et al., 2006; Vesa et al., 1995), Joubert syndrome (Lambert et al., 1989), peroxisomal diseases (Ek et al., 1986) and Senior Løken syndrome (Ellis et al., 1984).

3. Cone disorder mechanisms

3.1. Phototransduction cascade

The processes involved in the conversion of light into an electric neural signal are called phototransduction. The phototransduction cascade takes place in the outer segments of the rod and cone (Fig. 4, upper right panel) photoreceptors. Defects in various components of the phototransduction cascade can lead to CD: the red and green opsins, the cone transducin α subunit, the cone phosphodiesterase α' and γ subunits, the cone-specific cGMP-gated α and β subunits, the retinal guanylyl cyclase-1, and the voltage-gated potassium channel subunit.

Deletions of, or mutations in, the red and green opsin genes may cause color blindness (see 2.2.4.). A gene conversion event in which exon 3 of the red opsin gene, carrying the p.Trp177Arg variant, was transferred into the red opsin gene, was shown to underlie X-linked COD (Gardner et al., 2010). Mutations in the *GNAT2*-encoded α -subunit of cone transducin leads to ACHM (Kohl et al., 2002; Sundin et al., 2000; Wissinger et al., 2001). The identified mutations are null alleles, which are predicted to prevent either the formation of the trimeric transducin protein complex or its interaction with cone opsin and phosphodiesterase- γ (Aligianis et al., 2002; Kohl et al., 2002). Gene defects in *PDE6C* and *PDE6H*, encoding the α' and γ subunits of the cone cGMP phosphodiesterase, are a cause of ACHM and COD (Kohl et al., 2012; Thiadens et al., 2009a). Mutations in the *PDE6C* gene are null alleles leading to absence of the α' subunit, or missense mutations causing a loss or reduction of the catalytic activity resulting in reduced hydrolysis of cGMP (Chang et al., 2009; Grau et al., 2011). The absence of transducin or phosphodiesterase activity can be considered functionally analogous since in both cases the phototransduction cascade is interrupted and the photoreceptor remains in the dark state (Chang et al., 2009).

Mutations in the *CNGA3* and *CNGB3* genes encoding the α - and β -subunits of the cone cGMP-gated channel can cause ACHM and COD (Kohl et al., 2000, 1998; Sundin et al., 2000; Wissinger et al., 2001). A defect or lack of the cGMP-gated channel impairs the resting state dark current and the establishment of a proper cone photoreceptor membrane potential (Chang et al., 2009), causing apoptosis by perpetual influx of calcium ions (Biel et al., 1999; Thiadens et al., 2012a). The majority of *CNGB3* mutations are truncating, resulting in the absence or altered protein levels of the β -subunit (Pang et al., 2010). Amino acid substitutions in the highly conserved *CNGA3* protein have an even more severe phenotypic impact. The reason may lie in the fact that *CNGA3* can form a functional channel in the absence of *CNGB3*, while *CNGB3* cannot establish the ion currents without the presence of *CNGA3* (Johnson et al., 2004; Matveev et al., 2010). *CNGA3* missense mutations can

Table 2
Non-syndromic cone disorder genes, their associated human phenotypes, animal models, and gene therapy studies.

Gene	Associated phenotypes	Expression site	Mouse model	Reference mouse model	Other animal model	Reference animal model	Potential function	Gene therapy model	Reference gene therapy
<i>ABCA4</i>	AR-COD, AR-CRD, AR-RP, AR-STGD1	Cones and rods	KO	(Golczak et al., 2008; Weng et al., 1999)	–	–	All-trans-retinal flippase	Mouse	(Allocca et al., 2008; Han et al., 2012; Kong et al., 2008)
<i>ADAM9</i>	AR-CRD	RPE	KO	(Weskamp et al., 2002)	Dog	(Goldstein et al., 2010; Kropatsch et al., 2010)	Outer segment-RPE junction protein	–	–
<i>AIPL1</i>	AD-CRD, AR-LCA	Cones and rods	KO	(Dyer et al., 2004; Liu et al., 2004; Ramamurthy et al., 2004)	–	–	PDE chaperone	Mouse	(Ku et al., 2011; Sun et al., 2010; Tan et al., 2009)
<i>BEST1</i>	AD-MD, AR-Bestrinopathy	RPE	KI, KO	(Marmorstein et al., 2006; Zhang et al., 2010)	Dog	(Zangerl et al., 2010)	Calcium channel	Dog	(Guziewicz et al., 2013)
<i>CIQTNF5</i>	AD-MD	RPE, lens and ciliary epithelium	Trapped, KI, KI, reporter ^b	(Chavali et al., 2011; Shu et al., 2011; Zambrowicz et al., 2003)	–	–	Unknown	–	–
<i>C8orf37</i>	AR-CRD, AR-RP	Cones and rods	–	–	–	–	Transport across the CC	–	–
<i>CACNA1F</i>	XL-CRD, XL-CSNB	ONL and INL	KO, spontaneous	(Chang et al., 2006; Mansergh et al., 2005; Specht et al., 2009)	Rat	(Zheng et al., 2012)	Calcium channel	–	–
<i>CACNA2D4</i>	AR-COD	Ubiquitously	Spontaneous	(Rueher et al., 2000)	–	–	Calcium channel	–	–
<i>CDHR1</i>	AR-CRD, AR-RP	Ubiquitously	KI, KO	(Boland et al., 2009; Rattner et al., 2001)	–	–	Involved in the assembly of OS discs	–	–
<i>CERKL</i>	AR-CRD, AR-RP	Cones and rods	KD, KD	(Garanto et al., 2012; Graf et al., 2008)	–	–	Sphingolipid metabolism	–	–
<i>CNGA3</i>	AR-ACHM, AR-COD	Cones	KO, spontaneous	(Biel et al., 1999; Hawes et al., 2006)	Sheep	(Reicher et al., 2010)	Subunit of cGMP-regulated cation channel	Mouse	(Michalakis et al., 2012; Pang et al., 2012)
<i>CNGB3</i>	AR-ACHM, AR-COD, AR-CRD	Cones	KO	(Ding et al., 2009)	Dog	(Sidjanin et al., 2002; Yeh et al., 2013)	Subunit of cGMP-regulated cation channel	Mouse, dog	(Carvalho et al., 2011; Komáromy et al., 2010)
<i>CRX</i>	AD-CRD, AR-AD- <i>de novo</i> LCA, AD-RP	Cones and rods	KO, chemically induced	(Furukawa et al., 1999; Won et al., 2011)	Cat	(Menotti-Raymond et al., 2010)	Transcription factor	Mouse	(Homma et al., 2013)
<i>EFEMP1</i>	AD-MD	RPE	KI, KO ^b , KI, KO	(Fu et al., 2007; Marmorstein et al., 2007; McLaughlin et al., 2007)	–	–	Unknown	–	–
<i>EFEMP1</i>	AD-MD	RPE	KI, KO ^b , KI, KO	(Fu et al., 2007; Marmorstein et al., 2007; McLaughlin et al., 2007)	–	–	Unknown	–	–
<i>ELOVL4</i>	AD-MD	Endoplasmatic reticulum	KO, KO, reporter, KI, KI, targeted	(Barabas et al., 2013; Cameron et al., 2007; Li et al., 2007; McMahon et al., 2007; Raz-Prag et al., 2006; Vasireddy et al., 2006)	Pig	(Sommer et al., 2011)	Catalyzing very-long-chain fatty acid synthesis	–	–
<i>EYS</i>	AR-CRD, AR-RP	Cones and rods	No mouse ortholog	–	–	–	Photoreceptor morphogenesis and maintenance	–	–
<i>FSCN2</i>	AD-MD, AD-RP	Cones and rods	Spontaneous, KO, KO	(Johnson et al., 2008; Yokokura et al., 2005)	–	–	Actin structure assembly of CC plasma membrane; photoreceptor disc formation	–	–

<i>GNAT2</i>	AR-ACHM	Cones	Spontaneous, spontaneous	(Chang et al., 2006; Jobling et al., 2013)	–	–	Subunit of cone transducin	Mouse	(Alexander et al., 2007)
<i>GUCA1A</i>	AD-COD, AD-CRD	Cones and rods	KI, KO, KO	(Buch et al., 2011; Mendez et al., 2001; Mendez and Chen, 2002)	–	–	Ca ²⁺ -activated interactor of GUCY2D	Mouse	(Jiang et al., 2011)
<i>GUCA1B</i>	AD-MD, AD-RP	Cones and rods	KO, KO	(Makino et al., 2008; Mendez et al., 2001)	–	–	Ca ²⁺ -activated interactor of GUCY2D	–	–
<i>GUCY2D</i>	AD-CRD, AR-CRD, AR-LCA	Cones and rods	Reporter, reporter, KO	(Hu et al., 2007; Leinders-Zufall et al., 2007; Walz et al., 2007)	Pig, zebrafish	(Kostic et al., 2013; Stiebel-Kalish et al., 2012)	Generation cGMP	Mouse	(Boye et al., 2013)
<i>HMCN1</i>	AD-MD	RPE	–	–	–	–	Unknown	–	–
<i>IMPG1</i>	AD-MD	Interphotoreceptor space	–	–	Rhesus macaque	(Singh et al., 2007)	Unknown	–	–
<i>KCNV2</i>	AR-CDSRR	Cones and rods	–	–	–	–	Ion channel subunit	–	–
<i>NR2E3</i>	AR-ESC, AR-RP	Neural retina	KO, spontaneous	(Akhmedov et al., 2000; Chang et al., 2002)	–	–	Transcription factor	–	–
<i>OPN1LW</i>	XL-COD	Cones	–	–	–	–	Red-light sensitive opsin	–	–
<i>OPN1MW</i>	XL-COD	Cones	KI	(Smallwood et al., 2003)	–	–	Green light sensitive opsin	–	–
<i>PDE6C</i>	AR-ACHM, AR-COD	Cones	Spontaneous	(Chang et al., 2005)	–	–	Phosphodiesterase subunit α'	–	–
<i>PDE6H</i>	AR-ACHM, AR-COD	Cones	–	–	–	–	Phosphodiesterase subunit γ	–	–
<i>PITPNM3</i>	AD-CRD	Retina (rat)	–	–	–	–	Membrane turnover of photoreceptor cells (transport)	–	–
<i>PROM1</i>	AD-STGD, AR-CRD	Ubiquitously	Reporter, KI, KO, reporter	(Nishide et al., 2009; Shmelkov et al., 2008; Zacchigna et al., 2009; Zhu et al., 2009)	–	–	Photoreceptor membrane morphogenesis	–	–
<i>PRPH2</i>	AD-CRD, AD-MD, AD-RP,	Cones and rods	KI, spontaneous ^b , chemically induced	(McNally et al., 2002; Nystuen et al., 2008)	–	–	Membrane morphogenesis	Mouse	(Barber et al., 2013; Sarra et al., 2001)
<i>RAB28</i>	AR-CRD	Ubiquitous	–	–	–	–	Transport towards the CC	–	–
<i>RAX2</i>	^a CRD	ONL and INL	–	–	–	–	Transcription factor	–	–
<i>RIMS1</i>	AD-CRD	Presynaptic ribbons in retina and brain	KO, KI ^b , KO, floxed	(Kaesler et al., 2008; Schoch et al., 2002)	–	–	Neurotransmitter release and synaptic plasticity	–	–
<i>RP1L1</i>	AD-MD	Cones and rods	KO	(Yamashita et al., 2009)	–	–	Stabilization of microtubules	–	–
<i>RPGR</i>	XL-CRD, XL-RP	Cones and rods	Reporter, targeted, spontaneous	(Hong et al., 2000; Huang et al., 2012; Thompson et al., 2012)	Dog, dog	(Zhang et al., 2002b)	Transport across the CC	Dog	(Beltran et al., 2012)
<i>RPGRIP1</i>	AR-CRD, AR-LCA	Cones and rods	KO, chemically induced ^b	(Zhao et al., 2003)	Dog	(Kuznetsova et al., 2012)	Transport across the CC, intracellular trafficking	Mouse, dog	(Lh�riteau et al., 2013; Pawlyk et al., 2010)
<i>SEMA4A</i>	AD-CRD, AD-RP	Ubiquitous	KO, trapped	(Kumanogoh et al., 2005; Rice et al., 2004)	–	–	Interactor of CRBP1 and endosomal sorting	–	–
<i>TIMP3</i>	AD-Sorsby fundus dystrophy	RPE	Reporter ^b , KO, KO ^b , KO, KO, KI	(Janssen et al., 2008; Kawamoto et al., 2006; Leco et al., 2001; Weber et al., 2002)	–	–	Extracellular matrix remodeling	–	–
<i>TULP1</i>	AR-COD, AR-CRD, AR-RP	Cones and rods	KO	(Ikeda et al., 2000)	–	–	Transport towards the CC	–	–
<i>UNC119</i>	AD-CRD	Neural retina	KO	(Ishiba et al., 2007)	–	–	Transport across the CC	–	–

ACHM, achromatopsia; AD, autosomal dominant; AR, autosomal recessive; CD, cone dystrophy; *CDH11*, encodes protocadherin 21; CDRSS, cone dystrophy with supranormal rod response; CRD, cone-rod dystrophy; CC, connecting cilium; CSNB, congenital stationary night blindness; ESC, enhanced S-cone syndrome; KD, knockdown; KI, knock-in; KO, knockout; LCA, Leber congenital amaurosis; MD, macula dystrophy; *RAX2*, retina and anterior neural fold homeobox 2, encodes QRX; RP, retinitis pigmentosa; RPE, retinal pigment epithelium; OS, outer segment; XL, X-linked. aa, amino acids; bp, basepair; ERG, electroretinogram; ORF, open reading frame.

^a Mode of inheritance is unknown.

^b Mouse Genome Informatics direct data submission.

lead to an interfering conformational change of the active channel due to an altered secondary structure (Matveev et al., 2010). The impaired channel will cause cellular mistrafficking (Liu and Varnum, 2005; Reuter et al., 2008) and altered targeting to the plasma membrane due to impaired surface expression (Ding et al., 2010; Koeppen et al., 2008).

Remarkably, unlike COD and CRD, autosomal dominant inheritance has not been observed for ACHM, despite the fact that many cone-specific proteins act in multimeric complexes in which dominant-negative disease mechanisms would be plausible.

The *KCNV2* gene encodes a voltage-gated potassium channel subunit in cone and rod photoreceptors and mutations cause COD with supranormal rod responses on ERG. The subunit encoded by *KCNV2* is unable to form a functional potassium channel but needs heteromerization with other channel components, thereby altering the potassium current in the cell and affecting its excitability potential (Czirjak et al., 2007; Ottuschytsch et al., 2002). It is unclear how mutations in this gene cause repolarization disturbances in rods (Wissinger et al., 2008; Wu et al., 2006).

Specific heterozygous *GUCY2D* missense mutations are a cause of AD CRD, whereas homozygous or compound heterozygous inactivating mutations in this gene can cause AR-LCA. *GUCY2D* encodes the membrane-bound retinal guanylyl cyclase-1 protein (RetGC-1), which is expressed in both types of photoreceptors but predominantly in the cone outer segment (Gregory-Evans et al., 2000; Kelsell et al., 1998; Kitiratschky et al., 2008; Payne et al., 2001). In mammalian photoreceptor cells RetGC-1 and RetGC-2 together synthesize cyclic 3', 5'-guanosine monophosphate (cGMP) from guanosine triphosphate. RetGC-1 restores the Ca²⁺-sensitive cGMP levels after light activation of the phototransduction cascade, together with its associated activator proteins *GUCA1A* and *GUCA1B* (Hunt et al., 2010). Cyclase activity is regulated by Ca²⁺, which binds to the GC-associated proteins, GCAP1 and GCAP2 encoded by *GUCA1A* and *GUCA1B*, respectively. The majority of dominant missense mutations causing AD COD and AD CRD are found in the Ca²⁺-binding EF hands of the proteins. Similar to the dominant *GUCY2D* mutations, these mutations generally alter the cyclase sensitivity to inhibit the Ca²⁺ levels after a light flash.

3.2. Retinoid cycles

To maintain the phototransduction cascade, recycling of the chromophore all-*trans*-retinal to 11-*cis*-retinal is required. This process is referred to as the retinoid or visual cycle. The rod and cone visual cycles take place in their respective outer segments, and the RPE cells (Fig. 4, left upper panel). Moreover, part of the visual cycle of the cones takes place in the cone OS and the Müller cells (Fig. 4, left middle panel). Although several genes encoding proteins of the retinoid cycles have been found to be defective in inherited retinal dystrophies, only the *ABCA4* and *SEMA4A* genes are implicated in CDs (Table 2).

Upon photo-excitation all-*trans*-retinal dissociates from opsin and is subsequently transferred to the cytoplasmic space by *ABCA4*. In rods, *ABCA4* is located at the rim of the outer segments discs and essential in the transport of all-*trans*-retinal from the inner to the outer leaflet of the disks through an *ABCA4*-mediated flippase of N-retinylidene-phosphatidylethanolamine (PE), the Schiff base conjugate of retinal and PE. In the cytoplasm, all-*trans*-retinal separates from PE and is converted to all-*trans*-retinol (Molday et al., 2000; Sun et al., 1999; Sun and Nathans, 1997; Weng et al., 1999). In cones, N-retinylidene-PE is translocated from the exocytosolic leaflet (lumen/extracellular) to the cytoplasmic leaflet, and upon dissociation from PE, all-*trans*-retinal is reduced to all-*trans*-retinol by retinol dehydrogenase 8 (RDH8) (Fig. 4, left upper panel) (Maeda et al., 2007; Miyazono et al., 2008).

A defective *ABCA4* protein leads to the accumulation of A2E in RPE cells which basically consists of all-*trans*-retinal conjugated to N-retinylethanolamine (N-retinylidene-N-retinylethanolamine; N-retinylidene-PE) and another all-*trans*-retinal molecule cells (Quazi et al., 2012; Radu et al., 2004), which is toxic to these cells in higher concentrations (Sparrow et al., 2003).

In cone and rod photoreceptors, all-*trans*-retinal is converted to all-*trans*-retinol (i.e. vitamin A), and absorbed by the RPE cell. In these cells, vitamin A is converted to all-*cis*-retinal and recycled to be introduced back into the phototransduction cascade (Travis et al., 2007). Under light conditions cones have a higher demand for vitamin A compared to rods, which can be provided through an alternate visual cycle between the cone photoreceptor cells and the Müller cells. In the fovea, Müller cells exist in a 1:1 ratio to cones. In cone-dominated retinas (from ground squirrel and chicken) it was found that all-*trans*-retinol was isomerized to 11-*cis*-retinol directly, without the intermediate molecule all-*trans*-retinyl (Mata et al., 2002). Recently, Kaylor and colleagues showed that all-*trans*-retinol is isomerized by dihydroceramide desaturase-1 to 11-*cis*-retinol, 9-*cis*-retinol and 13-*cis*-retinol, of which 11-*cis*-retinol is subsequently bound to cellular retinal-binding protein (CRALBP). The interphotoreceptor retinoid-binding protein (IRBP) transports 11-*cis*-retinol to the cone OS. 9-*cis*-retinol diffuses directly to the interphotoreceptor matrix and into cone OS, and together with 11-*cis*-retinol is oxidized by an unknown retinol dehydrogenase to 9/11-*cis*-retinal which subsequently is combined with apo-opsin to form a new chromophore (Kaylor et al., 2013). Although more knowledge on the cone visual cycle has been gained, compared to the rod cycle challenges remain regarding the differences between the cycles. More studies could possibly address these challenges, potentially revealing novel candidate genes for CD.

Semaphorin 4A (*SEMA4A*) plays a role in endosomal sorting in the RPE (Fig. 4, left upper panel). As a response to oxidative stress, *SEMA4A* acts as a switch converting endosomal sorting in the lysosome to exosomal release, thereby preventing light-induced photoreceptor apoptosis. In the absence of oxidative stress, *SEMA4A* sorts retinoid-binding proteins with retinoids, a RAB11-facilitated process by which 11-*cis*-retinal is regenerated and transported back to photoreceptors (Toyofuku et al., 2012).

3.3. Photoreceptor development and structure

During development, photoreceptor specification is initiated by transcription factors OTX2 and RB by influencing the multipotent retinal neuroepithelial cells to exit the cell cycle. It is hypothesized that CRX is the competence factor in photoreceptor precursor cells after mitosis (Oh et al., 2007). Cells that only express CRX have the fate to become cone precursors, while NRL-expressing cells will develop into rod photoreceptor cells with subsequent expression of NR2E3 (Oh et al., 2007). The transcription factor RAX2 (QRX) is thought to synergistically increase the transactivating function of CRX and NRL and also to interact with CRX (Wang et al., 2004). Other, as yet unknown transcription factors are necessary to complete the development to mature photoreceptors.

Dominant gain-of-function mutations in *CRX* were found to be a cause of AD CRD (Freund et al., 1997), by impairing CRX-mediated transcriptional regulation of photoreceptor genes (Chen et al., 2002). Recessive loss-of-function, and dominant mutations in *NR2E3* cause enhanced S-cone syndrome, AR RP and rod related syndromes (Escher et al., 2009; Haider et al., 2000; Schorderet and Escher, 2009; Yzer et al., 2013). The molecular mechanism underlying phenotypes due to *NR2E3* mutations involves the absence of the NR2E3 repressor function on cone-specific gene promoters, either by the absence of NR2E3 protein because of nonsense mutations or aberrant splicing, absence of DNA binding because of

mutations in the DNA-binding domain, or impaired co-repressor binding because of mutations in the ligand-binding domain (Roduit et al., 2009).

The rod photoreceptor outer segments represent a unique and complex example of specialized sensory cilia by their dense stacks of rhodopsin-laden discs. Disc renewal takes place at the proximal side and it has been estimated that 10% of the rod photoreceptor discs at the distal tips of the OS in humans are removed every day by undergoing phagocytosis by the overlying RPE cells (Young, 1967). The process of disc morphogenesis is critical for the viability of the photoreceptor cells as shown by several vertebrate models, where blockage of disc morphogenesis resulted in cell death and retinal degeneration (Eckmiller, 1987; Steinberg et al., 1980). A relevant difference between cone and rod photoreceptors is the continuity of the disc membranes in cones and the presence of separate discs in rods.

The transmembrane protein peripherin/RDS forms homotetramers, or heterotetramers with ROM1. Some heterozygous variants in the gene encoding RDS, *PRPH2*, are associated with AD cone disorders (Kitiratschky et al., 2011; Nakazawa et al., 1996a, 1996b; Renner et al., 2009). Other heterozygous variants in *PRPH2*, in combination with heterozygous variants in *ROM1*, are associated with digenic RP (Dryja et al., 1997; Kajiwara et al., 1994; Poloschek et al., 2010). These molecules are proposed to play a critical role in disk membrane morphogenesis and to keep the rod discs in a flattened configuration by connecting to similar molecules on the other side of the disc through disulphide bridges (Fig. 4, left lower panel). Possibly, RDS has a similar function in cones to flatten the invaginations.

PROM1 interacts with protocadherin 21 (PCDH21) and actin filaments, which are also crucial for disk membrane morphogenesis. For ADAM9 it has been suggested that it may be involved in adhesion at the junction of the outer segments (OS) and the RPE. Alternatively, the transmembrane ADAM9 protein may be involved in the remodeling of the extracellular matrix between the RPE and the OS or in the shedding of factors essential for the maintenance of the extracellular matrix (Parry et al., 2009). *FSCN2* and *ELOVL4*, two genes involved in AD macular degeneration (Ambasudhan et al., 2004; Wada et al., 2003), are expressed in different parts of the photoreceptor cells and are also thought to have a role in maintaining the structure and/or physiological function of photoreceptor cells.

3.4. Transport processes

The narrow 'channel' or 'conveyor belt' connecting the inner segment with the outer segment of the photoreceptor cells is called the connecting cilium (CC; see Fig. 4, right lower panel). In the process of vision, transport of proteins from the inner segments critically occurs through docking at the basal body (or adjacent membrane) and subsequent transport via the CC towards the outer segment (Insinna and Besharse, 2008). Intraflagellar transport (IFT) complexes tightly regulate the anterograde flow of proteins necessary for the assembly, maintenance and renewal of outer segment discs (Li et al., 2012) as well as the retrograde transport of proteins.

Several proteins involved in CD have been identified at the CC. These proteins include AIPL1, C8orf37, RAB28, RPGR, RPGRIP1, TULP1, and UNC119. Mutations in *RPGR* causing COD are localized in ORF15, a highly repetitive region coding for a glutamic acid and glycine-rich C-terminal domain, while mutations causing RP are found throughout the protein. It has been hypothesized that the phenotype is determined by the type of opsin which is mis-localized, depending on the type of mutation (Hong et al., 2000; Zhao et al., 2003). Alternatively, the genetic background may

determine the disease outcome to be cone-dominated or rod-dominated (Brunner et al., 2010).

The transition zone protein RPGR has a wide expression, but mutations predominantly affect photoreceptor function, with few cases of hearing loss, sino-respiratory infections and sperm dysfunction (Iannaccone et al., 2004; Koenekoop et al., 2003; van Dorp et al., 1992; Zito et al., 2003). RPGR binds to RAB8a (Anand and Khanna, 2012), and via crystal modeling it was proposed that RPGR has an interplay with PDE δ and Arl2/3 to regulate ciliary targeting of farnesylated cargo (Wätzlich et al., 2013). RPGRIP1 is linked to cilium integrity with RPGR via Nek4 serine/threonine kinase (Coene et al., 2011) and localizes exclusively to the photoreceptor CC. Absence of RPGRIP1 in mice resulted in a strongly decreased formation of photoreceptor outer segments and a rapid degeneration of these neurons, leading to vision loss (Won et al., 2009).

AIPL1 functions as a chaperone of rod PDE6 and interacts with its α -, β -, and γ -subunits (Kolandaivelu et al., 2009) and is thereby indirectly also involved in the phototransduction cascade. The cone PDE6 α' but not the γ subunit carries a carboxy-terminal prenylation motif (as do the rod α and β PDE6 subunits), and it has been hypothesized that AIPL1 also acts as a chaperone for cone PDE6 (Kirschman et al., 2010). It recently has been shown that AIPL1 is essential for cone PDE6 stability (Kolandaivelu et al., 2013). AIPL1 is necessary for proper assembly of the rod PDE6-complex (Kolandaivelu et al., 2009) and also functions as a chaperone of other farnesylated proteins. The absence of AIPL1 results in disorganized rod and cone outer segments, although presence of viable rod cells may prevent a rapid degeneration (Kirschman et al., 2010). Interestingly, null mutations in RAB28 were recently found to be associated with AR CRD (Roosing et al., 2013). RAB28 belongs to a superfamily (>60 members in humans) of small GTPases that fulfill a myriad of intracellular transport functions. Strikingly, RAB28 is uniquely farnesylated at its carboxy terminus, whereas almost all other RABs contain two geranylgeranyl groups for membrane attachment and very few RABs can be farnesylated or geranylgeranylated. The expression of RAB28, as is the case for most RABs, is not restricted to the retina. It is not known why mutations in RAB28 only result in a retinal phenotype.

UNC119, also known as Retina Gene 4 protein (RG4), has been shown to be crucial for transducin transport in the absence of light (Zhang et al., 2011). In one mouse model UNC119 can dissociate transducin subunits from each other and the membrane, and subsequently inhibits rhodopsin-dependent activation of transducin (Gopalakrishna et al., 2011). Furthermore, UNC119 has the capacity of binding myristoylated proteins, e.g. NPHP3, which is regulated by the small GTPase ARL3 (Wright et al., 2011).

Mutations in the gene coding for RIMS1 are a cause of AD CRD, which is characterized by a progressive loss of photoreceptors along with retinal degeneration (Michaelides et al., 2005a). RIMS1 was found to be essential to short- and long-term synaptic plasticity by affecting the readily releasable pool of vesicles (Castillo et al., 2002; Schoch et al., 2002) and RIMS1 proteins were found to be required for normal Ca^{2+} -triggering of exocytosis (Schoch et al., 2006).

3.5. Synaptic transduction

A subset of genes associated with CD encode proteins that are localized in the synaptic region, i.e. CACNA1F, CACNA2D4, RIMS1, and UNC119. The transmission of L-glutamate at the photoreceptor synapses to the horizontal and bipolar cells is a calcium-dependent event. Transmitter release is increased with depolarization, as voltage-dependent calcium channels in a depolarized state have an increased capability of channel opening (Thoreson and Witkovsky,

1999). CACNA1F and CACNA2D4 are involved in a continuous calcium-dependent transmitter release and when disturbed cause CD. The reduction of functional calcium-channel densities in synaptic terminals may lead to inefficient photoreceptor-signal transmission and may account for the electronegative ERG (Wycisk et al., 2006). The RIMS1 protein plays a role in basic synaptic vesicle release as well as long- and short-term pre-synaptic plasticity (Castillo et al., 2002; Coppola et al., 2001; Schoch et al., 2002). The RIMS1 p.Arg655His missense mutation identified in CRD abolishes the hyperpolarization of current activation, likely resulting in impaired synaptic transmission of ribbon synapses of the visual system (Miki et al., 2007).

UNC119 may also have an important function in photoreceptor neurotransmission as it also is localized at the ribbon synapses formed between photoreceptors and the horizontal and bipolar cells of the retina (Kobayashi et al., 2000).

3.6. Miscellaneous

Several other CD-associated proteins cannot be assigned to one of the five major functionalities of the cone photoreceptor, RPE cells, and Müller cells, and are listed below.

Sphingolipids consist of a sphingoid base linked to a variety of polar groups and fatty acid chains (Hannun and Obeid, 2008). CERKL is an endoplasmic reticulum and golgi apparatus membrane associated protein, which seems to be involved in the sphingolipid metabolism due to the shared homology with CERK (Tuson et al., 2009). However its exact role is currently unknown. Knockdown mice showed reduced levels of several sphingolipids, such as glucosylceramide or sphingomyelin. Enzymes in the synthesis/degradation pathway of these sphingolipids are associated with sphingolipidoses, which among other features also can show retinal degeneration (Garanto et al., 2013). Furthermore, ceramides are involved in oxidative stress and apoptosis, and it has been shown that CERKL protects from induced oxidative stress *in vitro* (Tuson et al., 2009). CERKL has been shown to localize in mouse cone photoreceptors and ganglion cells (Garanto et al., 2011, 2012; Vekslin and Ben-Yosef, 2010), and *in vitro* assays suggest that CERKL interacts with GUCA1A and GUCA1B (Nevet et al., 2012). Morpholino oligonucleotide injected zebrafish showed abnormal eye development with lamination defects, photoreceptor outer segment developmental abnormalities, reduced eye size and increased apoptosis of retinal cells, suggesting that CERKL is relevant for survival and protection of retinal tissue (Riera et al., 2013).

In humans, *PITPNM3* is shown to be expressed in the brain, spleen and ovary, although the analysis of expressed sequence tags predicted a wider expression pattern (Kohn et al., 2007; Lev et al., 1999). The zebrafish homologue of *PITPNM3* is predominantly expressed in the inner segments of cone photoreceptor cells (Elagin et al., 2000). In the rat expression however is seen throughout the retina in all cell layers including the inner segment and outer plexiform layers containing photoreceptor terminals with predominant expression in Müller cells (Tian and Lev, 2002). Members of the PITP-family play a role in multiple processes such as phospholipase C-mediated inositol signaling, ATP-dependent Ca²⁺-activated secretion, lipid metabolism, trafficking from Golgi-membranes and exocytosis (Lev, 2004). The importance of a PIT domain was observed in *rdgB* mutant flies with light-dependent retinal degeneration rescued by transfer of the PIT-domain (Milligan et al., 1997). The signaling pathway for mammalian *PITPNM3* is not completely understood (Kohn et al., 2007).

Extracellular matrix components or plasma membrane components proteins encoded by *BEST1*, *C1QTNF5*, *EFEMP1*, *HMCN1* and *TIMP3*, are expressed in the RPE. A heterozygous p.Ser163Arg variant in *C1QTNF5*, encoding the short-chain collagen CTRP5,

causes late-onset macular degeneration. It was proposed that mutant CTRP5, which is secreted by the RPE, is unable to fulfill its adhesive property between the RPE and Bruch's membrane (Hayward et al., 2003). Although the functions of fibulin-3 (*EFEMP1*) and fibulin-6 (*HMCN1*) are unknown, interaction of fibulin-3 with *TIMP3*, an inhibitor of matrix metalloproteinases, has been demonstrated. *TIMP3* mutations are a cause of Sorsby maculopathy, a drusen associated dystrophy (Klenotic et al., 2004). It has been hypothesized that misfolding and accumulation of mutant fibulin-3 underlies drusen formation although the protein itself is not a major component of the drusen (Marmorstein et al., 2002).

Another component of the rod and cone photoreceptor extracellular matrix is *IMPG1* (a.k.a. SPACR). Although its exact function is unknown, *IMPG1* could be important in RPE-photoreceptor attachment (Acharya et al., 1998). Alternatively, mutations in *IMPG1* lead to impaired metabolism of the photoreceptors and/or RPE resulting in an accumulation of vitelliform deposits in the retina (Manes et al., 2013).

RP1L1 was shown to closely interact with *RP1* via its two DCX domains, which functions in the assembly and stabilization of axonemal microtubules (Yamashita et al., 2009). Whereas autosomal recessive and dominant mutations in *RP1* lead to rod photoreceptor dysfunction, autosomal recessive variants in *RP1L1* lead to late-onset RP; heterozygous variants are associated with AD occult macular dystrophy (Akaori et al., 2010; Park et al., 2010; Sisk et al., 2010).

4. Mammalian models for cone disorders

4.1. Mouse models for cone disorders

To learn more about the etiology, progression, underlying disease mechanisms, and to explore treatment of CDs, rodent animal models have been used. Rodent models have significantly improved our knowledge of retinal diseases as the disease process can be followed entirely, and invasive studies can be done. The life span and development of these animals permit a degenerative process to be followed in a matter of weeks to months also enabling thereby the effects of treatment to be monitored. The largest disadvantage of the mouse as a model for CD is the lack of the cone-dominated region or macula in mice, as well as the fact that humans have genes encoding three different types of cones (long, middle and short wavelength), whereas the mouse only contains cones sensitive for middle and short wavelengths (Bridges, 1959). Therefore, retinal phenotypes may differ significantly between mice and humans. In some cases, mice indeed do not mimic the human phenotype, as is the case for the *Adam9* (Weskamp et al., 2002), *Cerkl* (Garanto et al., 2012), *Gcap1* and *Gcap2* (Howes et al., 2002; Makino et al., 2008) mutant mice, or have not been described in detail for genes like *CDHR1*, *GUCY2D* and *RIMS1*. Secondly, the eye of the mouse differs in size and anatomy from humans hindering the development of gene delivery approaches that are suitable in human. Finally, the relatively short life span of a mouse can limit the relevance of the model. The ability to genetically modify mice has increased in the past decades. Besides genetic modification, a number of spontaneous and chemically-induced models have been identified. In Table 1, 42 genes are listed that are associated with non-syndromic CDs. Naturally occurring or generated mouse models are available for 31/42 (74%) CD-associated genes, including 33 knockouts, 14 knock-ins, two knockdowns, eight reporter models, three chemically induced, two targeted, two trapped, one floxed and 10 spontaneous mouse models (Table 2). For 10 of the CD associated genes, no mouse model is available. This is also true for the *EYS* gene, which represents the only CD-associated gene that is absent in the mouse (Abd El-Aziz et al., 2008; Collin et al., 2008). To

Table 3

Non-syndromic cone disorder genes, their human open reading frame sizes, the mouse model names, synonyms, and the retinal phenotype description.

Gene	aa	ORF (bp)	Model name ^b	Synonym ^b	Retinal phenotype description ^{b, c}
ABCA4	2273	6,819 ^a	tm1Ght, tm1Kpal	Abcr ⁻ , Abca4 ⁻	Delayed rod dark adaptation. Model for juvenile macular degeneration
ADAM9	819	2457	tm1Bbl	mdc9 ⁻	No retinal phenotype
AIPL1	384	1152	tm1Mad, tm1Tili, tm1Visu	Aipl1 ⁻ , Aipl1 ^h	Complete retinal degeneration and lack of ERG responses. Hypomorphic mutants display less severe retinal degeneration and impaired ERG responses
BEST1	605	1815	tm1.1Amar, tm1Lmar	Best1 ^{W93C} , Vmd2 ⁻	Altered eye electrophysiology
C1QTNF5	243	3914	Gt(OST522586)Lex, tm1.1Geno, tm1.1Itl, tm1.1(KOMP)Vlcg, rd6, rdx	C1qtnf5 ^{Ser163Arg} , C1qtnf5 ^{S163R} , C1qtnf5 ^{tm1.1Igl} , CTRP5 ^{S163R} , Mfrp ^{174delG}	Increased retina vasculature leakage, retinal degeneration, and features of late-onset macular degeneration Mice homozygous for the same knock-in generated by a different group are normal
C8orf37	208	624	–	–	–
CACNA1F	1977	5,931 ^a	tm1.1Sdie, tm1Ntbh, nob2	Cav1.4 ^{nob2} , nob2, Cacna1f ^{deltaEx14-17} , Cacna1f ^{G305x}	Impaired eye electrophysiology, abnormal retinal neuronal layer, bipolar cell, and horizontal cell morphology, and impaired retinal synapse morphology
CACNA2D4	1137	3411	lob	–	Severe loss of retinal signaling associated with abnormal photoreceptor ribbon synapses and cone-rod dysfunction
CDHR1	859	2577	tm1(crc)Kbal, tm1Nat	Pcdh21/Cre, prCAD ⁻	Progressive degeneration of retinal photoreceptor cells and a slight reduction in light responses
CERKL	558	1674	tm1.1Geno	–	No photoreceptor phenotype, retinal apoptosis and decreased amplitudes and increased implicit time of oscillatory potentials
CNGA3	676	2028	tm1Biel, cpfl5	CNG3 ⁻	Progressive loss of cone photoreceptor cells
CNGB3	809	2427	tm1Dgen	–	Cone degeneration and decreased photopic response
CRX	299	897	tm1Cic, tvrm65	Crx ⁻	A lack of photoreceptor outer segments and rod and cone activity, reduced expression of several photoreceptor- and pineal-specific genes, and altered circadian behavior
EFEMP1	494	1482	tm1Eap, tm1Lex, tm1Lmar, tm2Lmar	Efemp1 ^{R345W} , Efemp1 ^{ki}	Knock-out mice display a normal phenotype. Homozygous R345W mice develop deposits below the retinal pigment epithelium
ELOVL4	315	945	tm1Kzh, tm1Rayy, tm1Sie, tm1Wked, tm2Kzh	Elov14 ^{del} , E_mut ⁻ , Elov14 ^{270x}	Knock-out mice die before or around birth. Mice heterozygous for a null allele breed poorly and display mild retinal abnormalities
EYS	3144	9,432 ^a	–	–	–
FSCN2	517	1551	ahl8, tm1Sykk, tm2Sykk	Fscn2 ^{R109H} , Fscn2 ^P neo(-), Fscn2 ^S neo ⁻	Retinal generation with structural abnormalities of the outer segment and depressed rod and cone ERGs that worsen with age
GNAT2	354	1062	cpfl3, c.518A > G	–	Progressive degeneration of photoreceptors and normal ERG responses
GUCA1A	202	606	tm1.1Hunt, tm1Itl, tm1Jnc	COD3, GCAP ⁻ , GCAP1 ⁻ GCAP2 ⁻ , GCAPs ⁻	Photoreceptor degeneration and loss of cone and rod function
GUCA1B	201	603	tm1Amd, tm1Jnc	GCAP ⁻ , GCAP1 ⁻ GCAP2 ⁻ , GCAPs ⁻	Abnormal rod electrophysiology
GUCY2D	1103	3309	tm1Mom, tm1Sdm	GCD-ITL, Gucy2d ⁻	Not analyzed for retinal phenotype
HMCN1	5636	16,908 ^a	–	–	–
IMPG1	798	2394	–	–	–
KCNV2	545	1635	–	–	–
NR2E3	410	1230	tm1Dgen, rd7	–	Rosettes and a reduced number of nuclei in the retinal outer nuclear layer
OPN1LW	364	1092	–	–	–
OPN1MW	364	1092	tm1(OPN1LW)Nat	Opn1mw ^R , R	A knock-in allele encoding a derivative of the human red cone pigment results in hemizygous male and homozygous female mice with a ~45-nm red shift in retinal sensitivity
PDE6C	858	2574	cpfl1	–	Abnormal cone photoreceptor function
PDE6H	84	252	–	–	–
PITPNM3	974	2922	–	–	–
PROM1	865	2595	tm1.1(DTA)Toko, tm1Pec, tm1(crc/ERT2)Gilb, tm1Rafi	Prom1 ^{lacZ,DTA} , Prom1 ^{C-L}	Abnormal retina morphology, vasculature, and electrophysiology
PRPH2	346	1038	tm1Nmc, rd2, Nmf193	Prph2 ^{delta307} , rds-307, Prph2 ^{Rds} , Rd-2, rds, rds-, Rds, Rds ^{Rd2}	Slow retinal degeneration with thinning and loss of the outer nuclear layer, loss of photoreceptor outer segments, and increased numbers of Müller cells
RAB28	221	663	–	–	–
RAX2/QRX	184	552	–	–	–
RIMS1	1692	5,076 ^a	tm1Sud, tm3.1Sud, tm2Sud, tm3Sud	RIM1alpha ⁻ , RIM1alphabetabeta ⁻ , RIM1 S413A-KI, fRIM1, RIM1alphabetabeta ^{floxex}	No retinal phenotype
RP1L1	2401	7,203 ^a	tm1Jnz	–	Knock-out mice exhibit retinal photoreceptor abnormalities, including scattered outer segment disorganization, reduced ERG amplitudes, and progressive retinal rod cell degeneration

(continued on next page)

Table 3 (continued)

Gene	aa	ORF (bp)	Model name ^b	Synonym ^b	Retinal phenotype description ^{b, c}
<i>RPGR</i>	1152	3456	tm1Tili, tm1Wbrg, rd9	RPGR ⁻ , Rprgrdelta ^{exon4}	Ectopic location of cone opsins, reduced levels of rhodopsin in rod cells, and partial degeneration of both cone and rod photoreceptors by 2–6 months of age
<i>RPGRIP1</i>	1286	3858	tm1Tili, nmf247	RPGRIP ⁻	Photoreceptor cell dysmorphology. By 3 months of age mutant animals show near complete loss of photoreceptor cells
<i>SEMA4A</i>	761	2283	tm1Kik, Gt(OST393408)Lex	Sema4a ^{Gt22Lex}	Severe retinal degeneration with reduced retinal vessels, depigmentation and dysfunction of both rod and cone photoreceptors
<i>TIMP3</i>	212	636	tm1.1(KOMP)Vlcg, tm1Hest, tm1(KOMP)Vlcg, tm1Osy, tm1Rkko, tm1Web	timp-3 ⁻ , Timp-3-null, Timp3 ^{S156C}	Knock-out mice die prematurely with lethargy, ruffled hair, and a hunched posture, displaying impaired bronchiole branching, reduced alveologenesis and abnormal mammary gland involution. S156C knock-ins provide a mouse model for Sorsby fundus dystrophy
<i>TULP1</i>	542	1626	tm1Pjn	Tulp1 ⁻	Retinal degeneration
<i>UNC119</i>	240	720	tm1Gina		Retinal degeneration characterized by thinning of the outer nuclear layer of the retina that is visible at 6 months and progresses rapidly after 17 months to end-stage by 26 months

^a ORF sizes are larger than 4.7 kb and therefore not suitable targets for adeno-associated virus-therapy.

^b Data collected from MGI Jackson lab.

^c Phenotype among different models can vary.

date mouse model studies have contributed to our understanding of disease, in addition gene therapy has been successfully applied in 10 of these models (Table 1).

Compared to rod phototransduction studies in mice, studies in cones have been limited to ERG studies, mainly due to the low percentage of cones (3%) and fragility of the cone outer segments. To further study the mechanism, function and etiology of cones, mouse models were designed to increase the number of cones in the mouse retina (Fu, 1995). The Nrl knockout forces the cell fate of rod photoreceptor cells into cone-like photoreceptors (Daniele et al., 2005; Mears et al., 2001; Nikonov et al., 2005). In a second model, EGFP was expressed in mouse cones to increase detection and identification of cones (Fei and Hughes, 2001), and in the third model, rod phototransduction was blocked by a knockout of the rod transducin α -subunit (*Gnat1*^{-/-}) (Calvert et al., 2000).

4.2. Other animal models of cone disorders

Compared to small animal models like mouse or rat, larger animal models have a few advantages. Anatomically, the retinas of dogs and cats are more similar to those of humans, as they have a cone-rich area, which is similar to the macula. Chicken have a cone-rich retina in which cones outnumber the rods at 6:1, while in humans the cone-rod ratio is 1:20. Chicken cones have a higher density in the rod-free region analogous to the human fovea (Bruhn and Cepko, 1996; Thanos and Mey, 2001). Chicken also have retinal glia (Müller) cells, a fully sequenced genome and relatively low maintenance costs. The size of the eyes makes the chick especially suitable for experimental manipulation (Cebulla et al., 2012). Next to the cone-rich retina of chickens, pigs are also equipped with a cone-dominated retina. Although no naturally occurring cone disease related defects have been discovered in pigs, Mussolino et al. (2011) showed that the porcine retina is suitable for developing novel AAV-mediated therapies using AAV2/5 or AAV2/8 to transduce both RPE and photoreceptor cells without safety issues (Mussolino et al., 2011).

Xenopus laevis is an ideal animal model to study the role of the interphotoreceptor matrix in RPE-photoreceptor interactions (Garlipp and Gonzalez-Fernandez, 2013), due to the fact that 30% of its photoreceptors are cones, and because they have relatively large photoreceptors, which is helpful in cellular, transgenic and imaging studies (Moritz et al., 1999). The *Xenopus* genome is available

(Hellsten et al., 2010; James-Zorn et al., 2013) and strategies using morpholino oligonucleotide antisense knock-down offer a powerful reverse genetics approach (Gonzalez-Fernandez et al., 2011).

Currently there are only few large animal models which are suitable for investigating inherited CDs. Canine models with gene mutations in *ADAM9*, *BEST1*, *CNGB3*, *RPGR* and *RPGRIP1*, are currently used to develop therapy models. In three dog models the retinal degeneration was successfully treated (Beltran et al., 2012; Komáromy et al., 2010; Lhériteau et al., 2013) (Table 2). A great potential in the discovery of novel canine models for CDs resides in the several hundred dog breeds affected by progressive retinal atrophy with a currently unidentified gene defect (RWJ Collin (Nijmegen), K. Stieger (Giessen) and H. Lohi, (Helsinki), personal communications).

Other large animal models for CD are sheep, which carry a spontaneous nonsense mutation in *CNGA3* to investigate ACHM (Reicher et al., 2010), and a feline model with a single nucleotide deletion in *CRX* (Menotti-Raymond et al., 2010).

5. Therapeutics for cone disorders

Currently, to (partially) restore gene function in CDs, several strategies are being applied with the use of animal models. A specific vector is always necessary to deliver the target gene into the cell, as naked DNA is not able to enter the cell efficiently.

The success of retinal gene augmentation is dependent on the vector and delivery method. Vector choice depends on the size of the cDNA of the relevant gene, the type of targeted cells, stability of expression and immunogenicity. Although the eye is a complex organ, the advantages of the eye are its immune privileged nature, its small size, accessibility, and functional assessment.

Adeno-associated viruses (AAVs) have been successfully used as vectors for gene therapy. AAVs enable the incorporation of a healthy copy of the gene that is defective in the patient. An advantage of this technology is its low toxicity due to the absence of the original viral coding sequences as shown in its application in muscle, brain, liver, lung, RPE and the neural retina (Travis et al., 2007). A restriction of this technology is its limited cargo size, only enabling the transport of cDNAs of genes up to 4.7 kb, and therefore potentially are able to accommodate 36 of the 42 CD-associated genes (see Table 3). Putative immune responses to the viral capsid may also limit recurrent treatments.

In *Cnga3*^{-/-} mice, AAV5-mediated gene replacement therapy restored cone function and thereby visual processing. The non-functional cones were capable of producing photoreceptor responses and transferring the generated signals to the bipolar cells. Treated mice showed normalized levels of cGMP in the cones as well as a delayed cone cell death, and the inflammatory response typically seen in retinal degeneration was reduced (Michalakos et al., 2005, 2010). Treatment was successful when the subretinal injections were performed in 1- and/or 3-month-old knockout mice, and the therapeutic effect was still present after 8 months. Improved cone function using the AAV5 vector was confirmed in another *Cnga3* study (Pang et al., 2012).

A similar strategy was used to treat a deficiency of *CNGB3*-associated ACHM. In two canine models it was shown that long-term restoration of cone function and diurnal vision could be achieved by subretinal delivery of AAV5 vectors expressing human *CNGB3* under the control of a 2.1 kb human red cone opsin promoter (Komáromy et al., 2010). The same authors were also able to circumvent the unexplained reduction in therapeutic effect after 54 weeks in dogs by administration of ciliary neurotrophic factor (CNTF). Administration of this neuroprotective and axogenic factor for retinal ganglion cells however led to immature photoreceptors with shorter outer segments and reduced gene expression. This effect was reversible with photoreceptors returning to expected developmental maturity and function thereafter. This approach to photoreceptor replacement enabled successful gene therapy in dogs up to 42 months (Komáromy et al., 2013). As the treatment with CNTF in the dog model showed measurable phenotypic improvements, the first clinical trials in humans with *CNGB3* mutations using intraocular implants releasing CNTF are currently ongoing (<http://clinicaltrials.gov/ct2/show/NCT01648452?term=achromatopsia&rank=1>).

Long-term improvement of retinal function was also found in a study using AAV8 mediated therapy. In both M- and S-cones, the β -subunit of the CNG-channel could be detected after subretinal AAV8 vector injection. In addition, increased levels of the α -subunit of the CNG-channel were found, reduced cone death, improved density and a positive effect of the outer segment structure of the cone and subcellular compartmentalization of the cone opsins (Carvalho et al., 2011).

The current status of treatment of *CNGA3* and *-B3*-associated channelopathies in animal models have shown solid and encouraging results and hold great promises for future treatment of patients with similar defects (Schön et al., 2013). A human Phase 1 trial for patients with *CNGA3* mutations is being developed (B. Wissinger, personal communication). The human situation however may be more complex and limitations may occur due to the age-dependent results for *CNGB3*, which argues to treat only younger patients. Possibly, the same or a similar treatment with CNTF could create treatment opportunities for older patients too.

In *GNAT2* knockout mice, AAV-mediated therapy has also proven to be successful (Alexander et al., 2007). However, for those genes in which AAV-mediated therapy is not feasible due to their size, other strategies need to be developed. The *ABCA4* open reading frame (ORF) measures 6.8 kb and therefore an alternative approach using the nanoparticle (a.k.a. non-virus) mediated therapy has been applied. Compacted DNA nanoparticles were constructed with the human *ABCA4* cDNA and the IRBP or mouse opsin promoter. Nanoparticles have a high transfection efficiency in post-mitotic cells, are biodegradable, and cause minimal toxicity even after repeated doses to the eye, lung and brain (Han et al., 2012, and refs therein). This non-viral approach has been performed subretinally on *Abca4*^{-/-} mice. *ABCA4* transgene expression was identified up to 8 months after injection resulting in significant structural and functional rescue of Stargardt disease, with improved dark

adaptation recovery and reduced lipofuscin granules in the RPE (Han et al., 2012). These results suggest that nanoparticle-mediated gene delivery has the potential to target many diseases caused by mutations in large genes. Alternatively, lentiviral vectors can be used (Kumar et al., 2001) which can accommodate cDNAs up to ~10 kb. This strategy is currently also used for the development of *ABCA4* gene therapy. Equine infectious anemia virus (EIAV)-derived lentiviral vectors expressing either the human *ABCA4* gene or the *LacZ* reporter gene under the control of the constitutive (CMV) or photoreceptor-specific (Rho) promoters were subretinally injected in *Abca4*^{-/-} mice. High transduction efficiency of rod and cone photoreceptors and a significant reduction of accumulation of A2E were observed in these mice suggesting the potential of lentiviral gene therapy in treating *ABCA4*-associated maculopathies (Kong et al., 2008). Similar results in rabbit and macaque were shown in the study by Binley et al. (2013). In this study “StarGen” was used, a lentivirus vector containing a normal copy of the human *ABCA4* gene, which is currently in a Phase I/IIa stage with individuals affected with STGD1 (Binley et al., 2013) (<http://clinicaltrials.gov/ct2/show/NCT01367444?term=abca4&rank=6>).

One of the challenges for gene therapy is the limited time window to achieve a successful treatment outcome. Some CDs exhibit a fast progression of disease and therefore the window of opportunity of treatment is smaller compared to slow or non-progressive phenotypes. Hence, treatment opportunities may expand beyond our initial expectations now that SD-OCT and adaptive optics may determine the viability of the cone cell bodies, which have shown the capability of being reactivated in mice (Busskamp et al., 2010). In persons with very early onset CD, gene augmentation therapy however should ideally start as early as possible.

6. Future perspectives

6.1. Identification of CD-associated genes

WES, combined with homozygosity mapping or linkage analysis, has proven successful in the discovery of novel retinal disease genes (Estrada-Cuzcano et al., 2012; Roosing et al., 2013; Zeitz et al., 2013). In a recent Saudi Arabian study of predominantly AR inherited retinal dystrophies, ~80% of DNA samples analyzed using homozygosity mapping and/or WES were solved by the identification of mutations in either known or novel genes (Abu-Safieh et al., 2013). In six of 86 families with causal variants, mutations in different new genes were found. This suggests that most of the undiscovered CD genes (Fig. 3) are mutated in very low percentages of affected individuals.

In the next few years, WES and whole genome sequencing (WGS) will facilitate the identification of novel gene defects in individuals for which WES could not identify the pathologic defect. WGS can robustly identify heterozygous deletions, duplications, inversions, and intronic variants (Nishiguchi et al., 2013). However, proving causality of rare variants in candidate CD genes will be challenging, as in most cases only few family members are available for segregation analysis. This may be partially solved by testing large patient cohorts through collaborative efforts. In addition, the causality of novel variants can be tested through cellular and animal model studies.

6.2. Molecular diagnostics

Up to a few years ago it was not possible to, stabilize or improve impaired vision in persons with CD. With the emerging options for treatment of CD, early molecular diagnostics has become highly relevant. In addition, early molecular diagnosis may be important

in cases in which genetic defects are associated with extra-ocular features, some of which may develop later in life and be amenable to pre-symptomatic management, e.g. in nephronophthisis, in which the kidney is involved.

For some CD's (e.g. *ABCA4* in STGD1, *CNGB3* and *CNGA3* in ACHM, and *KCNV2* in CD with supranormal rod response), Sanger sequencing of one or a few genes will identify the causal variants in a significant proportion of cases. For the remaining phenotypes, novel high-throughput sequencing approaches may need to be used, in which either all CD-associated genes are analyzed or all human genes are analyzed in a single experiment by WES. WES may reveal the causal variants in elusive genes in 7.4–79% of cases, depending on the clinical subtype (Fig. 3). However causal variants may be missed due to the difficulty sequencing exons with a high GC content. To identify the non-exonic (deep-intronic) variants and structural variations, WGS and transcriptome analysis can be used.

6.3. Transcriptomics

Introns are riddled with rare variants that theoretically can have an impact on RNA splicing if they are situated in an intronic splice enhancer or inhibitor site, or if they increase the splicing potential of a cryptic splice site, leading to the transcription of an aberrant mRNA product. The latter was recently shown for *ABCA4*, as a few deep intronic variants led to aberrant splicing in persons with STGD1 (Braun et al., 2013). Farkas et al. (2013) identified 79,915 novel alternative splice events and more than one hundred novel genes expressed in human retinal tissue, which will aid the difficult task of discriminating benign from causal variants. 15–36% of the novel splicing events resulted in mRNAs with an open reading frame (Farkas et al., 2013). This demonstrates that the retinal transcriptome is more complicated than previously thought, and the knowledge of naturally occurring splice events may aid the interpretation of RNA analysis of known retinal disease genes in patients. Importantly, only approximately 35% of the genes involved in retinal dystrophies are expressed at high enough levels in lymphoblastoid cells to scrutinize the transcriptome from an individual's blood sample (K. Neveling, unpublished data).

Alternatively, photoreceptor precursor cells can be differentiated from patient's keratinocytes through generation of induced pluripotent stem cells (iPSC) (Tucker et al., 2013). iPSCs can be generated from adult somatic cells by expressing a set of transcription factors, and subsequently can be differentiated into retinal cells (Mekala et al., 2013, and refs therein). RNA analysis of such cells is likely to more closely mimic the situation in the diseased tissue, enabling the detection of splice defects that might not be detectable in lymphoblastoid cells. The generation of a homogeneous population of fully differentiated cells remains a challenge, in particular regarding the neural retina.

6.4. Alternative cone rescue strategies

A great promise in treating early onset degenerative diseases, like CD, are cell replacement therapies using retinal progenitor cells derived from embryonic stem cells (ESCs) or iPSCs. These cells could be very valuable in cell-based therapies. Proof of concept using mouse retinal progenitor cells harvested in a specific developmental time window (postnatal day 4–8) was obtained recently (Gonzalez-Cordero et al., 2013). It is critical to transplant a sufficient number of cells that can populate a significant fraction of the diseased retina. The transplanted cells differentiated into adult photoreceptor cells, were positioned at the correct location, and formed connections with bipolar cells (Gonzalez-Cordero et al., 2013; MacLaren et al., 2006; Pearson et al., 2010; West et al.,

2008), demonstrating the potential of this approach to rescue retinal function in future clinical trials.

7. Conclusions

The early aim of CD research has been the identification of the genetic bases of CD. Advances in this field compounded by technologies such as WES and WGS technologies have created a new era for molecular diagnostics in CD. In the next few years, the remaining genetic causes of CD will most likely be elucidated representing an enormous achievement. The prevalence of novel genetic defects however will be very low, and in particular regarding rare missense variants, functional modeling of their effects in animal models or cellular systems will be crucial to understand their mode of action. The ultimate aim remains the development of therapies that rescue cone photoreceptors. For the 31/42 CD-associated genes in which mammalian models are available, 14 have successfully been used for gene augmentation studies and a few human trials are underway. Nevertheless, large naturally occurring animal models, in particular canine models with progressive retinal atrophy, need to be identified for CDs as they can more closely mimic the human diseases and are a more relevant model with respect to the development of gene therapy. The rescue of cone photoreceptors not only is important to treat cone dysfunctions, but also will be crucial to maintain vision in rod-dominated diseases.

Acknowledgments

We would like to thank Louise F. Porter for critically reading this manuscript. This study was financially supported by the Foundation Fighting Blindness USA (grants BR-GE-0510-04890RAD, C-GE-0811-0545-RAD01) to A.I.d.H., and F.P.M.C., respectively, the Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, the Gelderse Blinden Stichting, the Landelijke Stichting voor Blinden en Slechtzienden, the Stichting Blinden-Penning, the Stichting Macula Degeneratie fonds, and the Rotterdamse Stichting Blindenbelangen (Uitzicht 2009-15) to F.P.M.C. and C.C.W.K. None of the authors have any financial interest or conflicting interest to disclose.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.preteyeres.2014.05.001>.

References

- Abd El-Aziz, M.M., Barragan, I., O'Driscoll, C.A., Goodstadt, L., Prigmore, E., Borrego, S., Mena, M., Pieras, J.I., El-Ashry, M.F., Safieh, L.A., Shah, A., Cheetham, M.E., Carter, N.P., Chakarova, C., Ponting, C.P., Bhattacharya, S.S., Antinolo, G., 2008. EYS, encoding an ortholog of *Drosophila* spacemaker, is mutated in autosomal recessive retinitis pigmentosa. *Nat. Genet.* 40, 1285–1287.
- Abu-Safieh, L., Alrashed, M., Anazi, S., Alkuraya, H., Khan, A.O., Al-Owain, M., Al-Zahrani, J., Al-Abdi, L., Hashem, M., Al-Tarimi, S., Sebai, M.A., Shamia, A., Ray-Zack, M.D., Nassan, M., Al-Hassnan, Z.N., Rahbeeni, Z., Waheeb, S., Alkharashi, A., Abboud, E., Al-Hazzaa, S.A.F., Alkuraya, F.S., 2013. Autozygome-guided exome sequencing in retinal dystrophy patients reveals pathogenic mutations and novel candidate disease genes. *Genome Res.* 23, 236–247.
- Acharya, S., Rayborn, M.E., Hollyfield, J.G., 1998. Characterization of SPACR, a sialoprotein associated with cones and rods present in the interphotoreceptor matrix of the human retina: immunological and lectin binding analysis. *Glycobiology* 8, 997–1006.
- Akatori, M., Tsunoda, K., Miyake, Y., Fukuda, Y., Ishiura, H., Tsuji, S., Usui, T., Hatase, T., Nakamura, M., Ohde, H., Itabashi, T., Okamoto, H., Takada, Y., Iwata, T., 2010. Dominant mutations in RP1L1 are responsible for occult macular dystrophy. *Am. J. Hum. Genet.* 87, 424–429.
- Akhmedov, N.B., Piriev, N.I., Chang, B., Rapoport, A.L., Hawes, N.L., Nishina, P.M., Nusinowitz, S., Heckenlively, J.R., Roderick, T.H., Kozak, C.A., Danciger, M., Davisson, M.T., Farber, D.B., 2000. A deletion in a photoreceptor-specific nuclear

- receptor mRNA causes retinal degeneration in the rd7 mouse. *Proc. Natl. Acad. Sci. U. S. A.* 97, 5551–5556.
- Alexander, J.J., Umino, Y., Everhart, D., Chang, B., Min, S.H., Li, Q., Timmers, A.M., Hawes, N.L., Pang, J.J., Barlow, R.B., Hauswirth, W.W., 2007. Restoration of cone vision in a mouse model of achromatopsia. *Nat. Med.* 13, 685–687.
- Aligianis, I.A., Forshew, T., Johnson, S., Michaelides, M., Johnson, C.A., Trembath, R.C., Hunt, D.M., Moore, A.T., Maher, E.R., 2002. Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2). *J. Med. Genet.* 39, 656–660.
- Allikmets, R., Singh, N., Sun, H., Shroyer, N.F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., Rattner, A., Smallwood, P., Li, Y., Anderson, K.L., Lewis, R.A., Nathans, J., Leppert, M., Dean, M., Lupski, J.R., 1997. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. *Nat. Genet.* 15, 236–246.
- Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S.R., Maguire, A., Rex, T.S., Di Vicino, U., Cuttillo, L., Sparrow, J.R., Williams, D.S., Bennett, J., Auricchio, A., 2008. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. *J. Clin. Investig.* 118, 1955–1964.
- Alström, C.H., Hallgren, B., Nilsson, L.B., Asander, H., 1959. Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness: a specific syndrome (not hitherto described) distinct from the Laurence-Moon-Bardet-Biedl syndrome: a clinical, endocrinological and genetic examination based on a large pedigree. *Acta Psychiatr. Neurol. Scand. Suppl.* 129, 1–35.
- Ambasudhan, R., Wang, X.F., Jablonski, M.M., Thompson, D.A., Lagali, P.S., Wong, P.W., Sieving, P.A., Ayyagari, R., 2004. Atrophic macular degeneration mutations in ELOVL4 result in the intracellular misrouting of the protein. *Genomics* 83, 615–625.
- Anand, M., Khanna, H., 2012. Ciliary transition zone (TZ) proteins RPGR and CEP290: role in photoreceptor cilia and degenerative diseases. *Expert Opin. Ther. Targets* 16, 541–551.
- Arikawa, K., Molday, L.L., Molday, R.S., Williams, D.S., 1992. Localization of peripherin/rds in the disk membranes of cone and rod photoreceptors: relationship to disk membrane morphogenesis and retinal degeneration. *J. Cell Biol.* 116, 659–667.
- Armstrong, J.D., Meyer, D., Xu, S., Elfervig, J.L., 1998. Long-term follow-up of Stargardt's disease and fundus flavimaculatus. *Ophthalmology* 105, 448–457 discussion 457–448.
- Barabas, P., Liu, A., Xing, W., Chen, C.K., Tong, Z., Watt, C.B., Jones, B.W., Bernstein, P.S., Krizaj, D., 2013. Role of ELOVL4 and very long-chain polyunsaturated fatty acids in mouse models of Stargardt type 3 retinal degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 110, 5181–5186.
- Barber, A.C., Hippert, C., Duran, Y., West, E.L., Bainbridge, J.W.B., Warre-Cornish, K., Luhmann, U.F., Lakowski, J., Sowden, J.C., Ali, R.R., Pearson, R.A., 2013. Repair of the degenerate retina by photoreceptor transplantation. *Proc. Natl. Acad. Sci. U. S. A.* 110, 354–359.
- Baum, L., Chan, W.M., Li, W.Y., Lam, D.S.C., Wang, P.B., Pang, C.P., 2003. ABCA4 sequence variants in Chinese patients with age-related macular degeneration or Stargardt's disease. *Ophthalmologica* 217, 111–114.
- Beltran, W.A., Cideciyan, A.V., Lewin, A.S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V.A., Fajardo, D.S., Roman, A.J., Deng, W.T., Swider, M., Aleman, T.S., Boye, S.L., Genini, S., Swaroop, A., Hauswirth, W.W., Jacobson, S.G., Aguirre, G.D., 2012. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. *Proc. Natl. Acad. Sci. U. S. A.* 109, 2132–2137.
- Berger, W., Kloeckner-Gruissem, B., Neidhardt, J., 2010. The molecular basis of human retinal and vitreoretinal diseases. *Prog. Retin. Eye Res.* 29, 335–375.
- Berson, E.L., Sandberg, M.A., Rosner, B., Sullivan, P.L., 1983. Color plates to help identify patients with blue cone monochromatism. *Am. J. Ophthalmol.* 95, 741–747.
- Biel, M., Seeliger, M., Pfeifer, A., Kohler, K., Gerstner, A., Ludwig, A., Jaisle, G., Fauser, S., Zrenner, E., Hofmann, F., 1999. Selective loss of cone function in mice lacking the cyclic nucleotide-gated channel CNG3. *Proc. Natl. Acad. Sci. U. S. A.* 96, 7553–7557.
- Binley, K., Widdowson, P., Loader, J., Kelleher, M., Iqbal, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., Ellis, S., Miskin, J., Fernandes, A., Wong, P., Allikmets, R., Bergstrom, C., Aaberg, T., Yan, J., Kong, J., Gouras, P., Prefontaine, A., Vezina, M., Bussieres, M., Naylor, S., Mitrophanous, K.A., 2013. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. *Investig. Ophthalmol. Vis. Sci.* 54, 4061–4071.
- Blacharski, P.A., 1988. *Fundus Flavimaculatus*. Raven Press, New York.
- Boland, M.J., Hazen, J.L., Nazor, K.L., Rodriguez, A.R., Gifford, W., Martin, G., Kupriyanov, S., Baldwin, K.K., 2009. Adult mice generated from induced pluripotent stem cells. *Nature* 461, 91–94.
- Boon, C.J., den Hollander, A.I., Hoyng, C.B., Cremers, F.P., Klevering, B.J., Keunen, J.E., 2008. The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS gene. *Prog. Retin. Eye Res.* 27, 213–235.
- Boon, C.J., Klevering, B.J., Cremers, F.P., Zonneveld-Vrieling, M.N., Theelen, T., den Hollander, A.I., Hoyng, C.B., 2009a. Central areolar choroidal dystrophy. *Ophthalmology* 116, 771–782, 782 e771.
- Boon, C.J., Klevering, B.J., Leroy, B.P., Hoyng, C.B., Keunen, J.E., den Hollander, A.I., 2009b. The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. *Prog. Retin. Eye Res.* 28, 187–205.
- Boon, C.J., van Schooneveld, M.J., den Hollander, A.I., van Lith-Verhoeven, J.J., Zonneveld-Vrieling, M.N., Theelen, T., Cremers, F.P., Hoyng, C.B., Klevering, B.J., 2007. Mutations in the peripherin/RDS gene are an important cause of multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus. *Br. J. Ophthalmol.* 91, 1504–1511.
- Boye, S.L., Peshenko, I.V., Huang, W.C., Min, S.H., McDoom, I., Kay, C.N., Liu, X., Dyka, F.M., Foster, T.C., Umino, Y., Karan, S., Jacobson, S.G., Baehr, W., Dizhoor, A., Hauswirth, W.W., Boye, S.E., 2013. AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. *Hum. Gene Ther.* 24, 189–202.
- Braun, T.A., Mullins, R.F., Wagner, A.H., Andorf, J.L., Johnston, R.M., Bakall, B.B., Deluca, A.P., Fishman, G.A., Lam, B.L., Weleber, R.G., Cideciyan, A.V., Jacobson, S.G., Sheffield, V.C., Tucker, B.A., Stone, E.M., 2013. Non-exomic and synonymous variants in ABCA4 are an important cause of Stargardt disease. *Hum. Mol. Genet.* 22, 5136–5145.
- Bridges, C.D., 1959. Visual pigments of some common laboratory mammals. *Nature* 184 (Suppl. 22), 1727–1728.
- Bruhn, S.L., Cepko, C.L., 1996. Development of the pattern of photoreceptors in the chick retina. *J. Neurosci.* 16, 1430–1439.
- Brunner, S., Skosyrski, S., Kirschner-Schwabe, R., Knobloch, K.P., Neidhardt, J., Feil, S., Glaus, E., Luhmann, U.F., Ruther, K., Berger, W., 2010. Cone versus rod disease in a mutant Rprg mouse caused by different genetic backgrounds. *Investig. Ophthalmol. Vis. Sci.* 51, 1106–1115.
- Buch, P.K., Mihelec, M., Cottrill, P., Wilkie, S.E., Pearson, R.A., Duran, Y., West, E.L., Michaelides, M., Ali, R.R., Hunt, D.M., 2011. Dominant cone-rod dystrophy: a mouse model generated by gene targeting of the GCAP1/Guca1a gene. *PLoS One* 6, e18089.
- Burgess, R., Millar, I.D., Leroy, B.P., Urquhart, J.E., Fearon, I.M., De Baere, E., Brown, P.D., Robson, A.G., Wright, A.G., Kestelyn, P., Holder, G.E., Webster, A.R., Manson, F.D., Black, G.C., 2008. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. *Am. J. Hum. Genet.* 82, 19–31.
- Busskamp, V., Duebel, J., Balya, D., Fradot, M., Viney, T.J., Siegert, S., Groner, A.C., Cabuy, E., Forster, V., Seeliger, M., Biel, M., Humphries, P., Paques, M., Mohand-Said, S., Trono, D., Deisseroth, K., Sahel, J.A., Picaud, S., Roska, B., 2010. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. *Science* 329, 413–417.
- Calvert, P.D., Krasnoperova, N.V., Lyubarsky, A.L., Isayama, T., Nicolo, M., Kosaras, B., Wong, G., Gannon, K.S., Margolskee, R.F., Sidman, R.L., Pugh Jr., E.N., Makino, C.L., Lem, J., 2000. Phototransduction in transgenic mice after targeted deletion of the rod transducin alpha subunit. *Proc. Natl. Acad. Sci. U. S. A.* 97, 13913–13918.
- Cameron, D.J., Tong, Z., Yang, Z., Kaminoh, J., Kamiyay, S., Chen, H., Zeng, J., Chen, Y., Luo, L., Zhang, K., 2007. Essential role of Elov4 in very long chain fatty acid synthesis, skin permeability barrier function, and neonatal survival. *Int. J. Biol. Sci.* 3, 111–119.
- Carvalho, L.S., Xu, J., Pearson, R.A., Smith, A.J., Bainbridge, J.W., Morris, L.M., Flieler, S.J., Ding, X.Q., Ali, R.R., 2011. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. *Hum. Mol. Genet.* 20, 3161–3175.
- Castillo, P.E., Schoch, S., Schmitz, F., Sudhof, T.C., Malenka, R.C., 2002. RIM1alpha is required for presynaptic long-term potentiation. *Nature* 415, 327–330.
- Cebulla, C.M., Zelinka, C.P., Scott, M.A., Lubow, M., Bingham, A., Rasiah, S., Mahmoud, A.M., Fischer, A.J., 2012. A chick model of retinal detachment: cone rich and novel. *PLoS One* 7, e44257.
- Chang, B., Grau, T., Dangel, S., Hurd, R., Jurkies, B., Sener, E.C., Andreasson, S., Dollfus, H., Baumann, B., Bolz, S., Artemyev, N., Kohl, S., Heckenlively, J., Wissinger, B., 2009. A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene. *Proc. Natl. Acad. Sci. U. S. A.* 106, 19581–19586.
- Chang, B., Hawes, N.L., Hurd, R.E., Davisson, M.T., Nusinowitz, S., Heckenlively, J.R., 2002. Retinal degeneration mutants in the mouse. *Vis. Res.* 42, 517–525.
- Chang, B., Hawes, N.L., Hurd, R.E., Wang, J., Howell, D., Davisson, M.T., Roderick, T.H., Nusinowitz, S., Heckenlively, J.R., 2005. Mouse models of ocular diseases. *Vis. Neurosci.* 22, 587–593.
- Chang, B., Heckenlively, J.R., Bayley, P.R., Brecha, N.C., Davisson, M.T., Hawes, N.L., Hirano, A.A., Hurd, R.E., Ikeda, A., Johnson, B.A., McCall, M.A., Morgans, C.W., Nusinowitz, S., Peachey, N.S., Rice, D.S., Vessey, K.A., Gregg, R.G., 2006. The nob2 mouse, a null mutation in *Cacna1f*: anatomical and functional abnormalities in the outer retina and their consequences on ganglion cell visual responses. *Vis. Neurosci.* 23, 11–24.
- Chavali, V.R., Khan, N.W., Cukras, C.A., Bartsch, D.U., Jablonski, M.M., Ayyagari, R., 2011. A CTRP5 gene S163R mutation knock-in mouse model for late-onset retinal degeneration. *Hum. Mol. Genet.* 20, 2000–2014.
- Chen, S., Wang, Q.L., Xu, S., Liu, L., Li, L.Y., Wang, Y., Zack, D.J., 2002. Functional analysis of cone-rod homeobox (CRX) mutations associated with retinal dystrophy. *Hum. Mol. Genet.* 11, 873–884.
- Clemett, R., 1991. Vitelliform dystrophy: long-term observations on New Zealand pedigrees. *Aust. N. Z. J. Ophthalmol.* 19, 221–227.
- Coene, K.L., Mans, D.A., Boldt, K., Gloeckner, C.J., van Reeuwijk, J., Bolat, E., Roosing, S., Letteboer, S.J., Peters, T.A., Cremers, F.P., Ueffing, M., Ropman, R., 2011. The ciliopathy-associated protein homologs RPGRIP1 and ROPGRIP1 are linked to cilium integrity through interaction with Nek4 serine/threonine kinase. *Hum. Mol. Genet.* 20, 3592–3605.
- Collin, R.W., Littink, K.W., Klevering, B.J., van den Born, L.I., Koenekoop, R.K., Zonneveld, M.N., Blokland, E.A., Strom, T.M., Hoyng, C.B., den Hollander, A.I., Cremers, F.P., 2008. Identification of a 2 Mb human ortholog of *Drosophila* eyes shut/spacemaker that is mutated in patients with retinitis pigmentosa. *Am. J. Hum. Genet.* 83, 594–603.

- Connell, G., Bascom, R., Molday, L., Reid, D., McInnes, R.R., Molday, R.S., 1991. Photoreceptor peripherin is the normal product of the gene responsible for retinal degeneration in the rds mouse. *Proc. Natl. Acad. Sci. U. S. A.* 88, 723–726.
- Coppola, T., Magnin-Luthi, S., Perret-Menoud, V., Gattesco, S., Schiavo, G., Regazzi, R., 2001. Direct interaction of the Rab3 effector RIM with Ca²⁺ channels, SNAP-25, and synaptotagmin. *J. Biol. Chem.* 276, 32756–32762.
- Cremer, F.P., van de Pol, D.J., van Driel, M., den Hollander, A.I., van Haren, F.J., Knoers, N.V., Tijmes, N., Bergen, A.A., Rohrschneider, K., Blankenagel, A., Pinckers, A.J., Deutman, A.F., Hoyng, C.B., 1998. Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in the Stargardt's disease gene ABCR. *Hum. Mol. Genet.* 7, 355–362.
- Czirjak, G., Toth, Z.E., Enyedi, P., 2007. Characterization of the heteromeric potassium channel formed by kv2.1 and the retinal subunit kv8.2 in *Xenopus* oocytes. *J. Neurophysiol.* 98, 1213–1222.
- Daniele, L.L., Lillo, C., Lyubarsky, A.L., Nikonov, S.S., Philp, N., Mears, A.J., Swaroop, A., Williams, D.S., Pugh Jr., E.N., 2005. Cone-like morphological, molecular, and electrophysiological features of the photoreceptors of the Nrl knockout mouse. *Investig. Ophthalmol. Vis. Sci.* 46, 2156–2167.
- Deutman, A.F., Pinckers, A.J., Aan de Kerk, A.L., 1976. Dominantly inherited cystoid macular edema. *Am. J. Ophthalmol.* 82, 540–548.
- Ding, X.Q., Fitzgerald, J.B., Quiambao, A.B., Harry, C.S., Malykhina, A.P., 2010. Molecular pathogenesis of achromatopsia associated with mutations in the cone cyclic nucleotide-gated channel CNGA3 subunit. *Adv. Exp. Med. Biol.* 664, 245–253.
- Ding, X.Q., Harry, C.S., Umino, Y., Matveev, A.V., Fliesser, S.J., Barlow, R.B., 2009. Impaired cone function and cone degeneration resulting from CNGB3 deficiency: down-regulation of CNGA3 biosynthesis as a potential mechanism. *Hum. Mol. Genet.* 18, 4770–4780.
- Dryja, T.P., Hahn, L.B., Kajiwar, K., Berson, E.L., 1997. Dominant and digenic mutations in the peripherin/RDS and ROM1 genes in retinitis pigmentosa. *Investig. Ophthalmol. Vis. Sci.* 38, 1972–1982.
- Dyer, M.A., Donovan, S.L., Zhang, J., Gray, J., Ortiz, A., Tenney, R., Kong, J., Allikmets, R., Sohocki, M.M., 2004. Retinal degeneration in Aip1-deficient mice: a new genetic model of Leber congenital amaurosis. *Brain Res. Mol. Brain Res.* 132, 208–220.
- Eckmiller, M.S., 1987. Cone outer segment morphogenesis: taper change and distal invaginations. *J. Cell Biol.* 105, 2267–2277.
- Ek, J., Kase, B.F., Reith, A., Bjorkhem, I., Pedersen, J.I., 1986. Peroxisomal dysfunction in a boy with neurologic symptoms and amaurosis (Leber disease): clinical and biochemical findings similar to those observed in Zellweger syndrome. *J. Pediatr.* 108, 19–24.
- Elagin, V.A., Elagina, R.B., Doro, C.J., Vihtelic, T.S., Hyde, D.R., 2000. Cloning and tissue localization of a novel zebrafish RdgB homolog that lacks a phospholipid transfer domain. *Vis. Neurosci.* 17, 303–311.
- Ellis, D.S., Heckenlively, J.R., Martin, C.L., Lachman, R.S., Sakati, N.A., Rimoin, D.L., 1984. Leber's congenital amaurosis associated with familial juvenile nephronophthisis and cone-shaped epiphyses of the hands (the Saldino-Mainzer syndrome). *Am. J. Ophthalmol.* 97, 233–239.
- Escher, P., Gouras, P., Roduit, R., Tiab, L., Bolay, S., Delarive, T., Chen, S., Tsai, C.C., Hayashi, M., Zermant, J., Merriam, J.E., Mermod, N., Allikmets, R., Munier, F.L., Schorderet, D.F., 2009. Mutations in NR2E3 can cause dominant or recessive retinal degenerations in the same family. *Hum. Mutat.* 30, 342–351.
- Estrada-Cuzcano, A.I., Neveling, K., Kohl, S., Banin, E., Rotenstreich, Y., Sharon, D., Falik-Zaccai, T.C., Hipp, S., Roepman, R., Wissinger, B., Letteboer, S.J., Mans, D.A., Blokland, E.A., Kwant, M.P., Gijsen, S.J., van Huet, R.A., Collin, R.W., Scheffer, H., Veltman, J.A., Zrenner, E., European Retinal Disease Consortium, den Hollander, A.I., Klevering, B.J., Cremers, F.P., 2012. Mutations in C8orf37, encoding a ciliary protein, are associated with autosomal-recessive retinal dystrophies with early macular involvement. *Am. J. Hum. Genet.* 90, 102–109.
- Farkas, M.H., Grant, G.R., White, J.A., Sousa, M.E., Consugar, M.B., Pierce, E.A., 2013. Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel transcribed sequence via significant alternative splicing and novel genes. *BMC Genomics* 14, 486.
- Fei, Y., Hughes, T.E., 2001. Transgenic expression of the jellyfish green fluorescent protein in the cone photoreceptors of the mouse. *Vis. Neurosci.* 18, 615–623.
- Fishman, G.A., Stone, E.M., Grover, S., Derlacki, D.J., Haines, H.L., Hockey, R.R., 1999. Variation of clinical expression in patients with Stargardt dystrophy and sequence variations in the ABCR gene. *Arch. Ophthalmol.* 117, 504–510.
- Franceschetti, A., 1963. Ueber tapeto-retinale Degenerationen in Kindesalter. Entwicklung und Fortschritt in der Augenheilkunde. Stuttgart, pp. 107–120.
- Francis, P.J., Johnson, S., Edmunds, B., Kelsell, R.E., Sheridan, E., Garrett, C., Holder, G.E., Hunt, D.M., Moore, A.T., 2003. Genetic linkage analysis of a novel syndrome comprising North Carolina-like macular dystrophy and progressive sensorineural hearing loss. *Br. J. Ophthalmol.* 87, 893–898.
- Freund, C.L., Gregory-Evans, C.Y., Furukawa, T., Papaioannou, M., Looser, J., Ploder, L., Bellingham, J., Ng, D., Herbrick, J.A., Duncan, A., Scherer, S.W., Tsui, L.C., Loutradis-Anagnostou, A., Jacobson, S.G., Cepko, C.L., Bhattacharya, S.S., McInnes, R.R., 1997. Cone-rod dystrophy due to mutations in a novel photoreceptor-specific homeobox gene (CRX) essential for maintenance of the photoreceptor. *Cell* 91, 543–553.
- Fu, L., Garland, D., Yang, Z., Shukla, D., Rajendran, A., Pearson, E., Stone, E.M., Zhang, K., Pierce, E.A., 2007. The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice. *Hum. Mol. Genet.* 16, 2411–2422.
- Fu, Y., 1995. Phototransduction in rods and cones. In: Kolb, H., Fernandez, E., Nelson, R. (Eds.), *Webvision: the Organization of the Retina and Visual System*. Salt Lake City (UT).
- Furukawa, T., Morrow, E.M., Li, T., Davis, F.C., Cepko, C.L., 1999. Retinopathy and attenuated circadian entrainment in Crx-deficient mice. *Nat. Genet.* 23, 466–470.
- Garanto, A., Mandal, N.A., Egido-Gabas, M., Marfany, G., Fabrias, G., Anderson, R.E., Casas, J., Gonzalez-Duarte, R., 2013. Specific sphingolipid content decrease in Cerkl knockdown mouse retinas. *Exp. Eye Res.* 110, 96–106.
- Garanto, A., Riera, M., Pomares, E., Permanyer, J., de Castro-Miro, M., Sava, F., Abril, J.F., Marfany, G., Gonzalez-Duarte, R., 2011. High transcriptional complexity of the retinitis pigmentosa CERKL gene in human and mouse. *Investig. Ophthalmol. Vis. Sci.* 52, 5202–5214.
- Garanto, A., Vicente-Tejedor, J., Riera, M., de la Villa, P., Gonzalez-Duarte, R., Blanco, R., Marfany, G., 2012. Targeted knockdown of Cerkl, a retinal dystrophy gene, causes mild affection of the retinal ganglion cell layer. *Biochim. Biophys. Acta* 1822, 1258–1269.
- Gardner, J.C., Michaelides, M., Holder, G.E., Kanuga, N., Webb, T.R., Mollon, J.D., Moore, A.T., Hardcastle, A.J., 2009. Blue cone monochromacy: causative mutations and associated phenotypes. *Mol. Vis.* 15, 876–884.
- Gardner, J.C., Webb, T.R., Kanuga, N., Robson, A.G., Holder, G.E., Stockman, A., Ripamonti, C., Ebenezer, N.D., Ogun, O., Devery, S., Wright, G.A., Maher, E.R., Cheetham, M.E., Moore, A.T., Michaelides, M., Hardcastle, A.J., 2010. X-linked cone dystrophy caused by mutation of the red and green cone opsins. *Am. J. Hum. Genet.* 87, 26–39.
- Gardner, J.C., Webb, T.R., Kanuga, N., Robson, A.G., Holder, G.E., Stockman, A., Ripamonti, C., Ebenezer, N.D., Ogun, O., Devery, S., Wright, G.A., Maher, E.R., Cheetham, M.E., Moore, A.T., Michaelides, M., Hardcastle, A.J., 2012. A novel missense mutation in both OPN1LW and OPN1MW cone opsin genes causes X-linked cone dystrophy (XLCOD5). *Adv. Exp. Med. Biol.* 723, 595–601.
- Garlipp, M.A., Gonzalez-Fernandez, F., 2013. Cone outer segment and Muller microvilli pericellular matrices provide binding domains for interphotoreceptor retinoid-binding protein (IRBP). *Exp. Eye Res.* 113, 192–202.
- Genead, M.A., Fishman, G.A., Rha, J., Dubis, A.M., Bonci, D.M., Dubra, A., Stone, E.M., Neitz, M., Carroll, J., 2011. Photoreceptor structure and function in patients with congenital achromatopsia. *Investig. Ophthalmol. Vis. Sci.* 52, 7298–7308.
- Golczak, M., Maeda, A., Bereta, G., Maeda, T., Kiser, P.D., Hunzelmann, S., von Lintig, J., Blauer, W.S., Palczewski, K., 2008. Metabolic basis of visual cycle inhibition by retinoid and nonretinoid compounds in the vertebrate retina. *J. Biol. Chem.* 283, 9543–9554.
- Goldstein, O., Mezey, J.G., Boyko, A.R., Gao, C., Wang, W., Bustamante, C.D., Anguish, L.J., Jordan, J.A., Pearce-Kelling, S.E., Aguirre, G.D., Acland, G.M., 2010. An ADAM9 mutation in canine cone-rod dystrophy 3 establishes homology with human cone-rod dystrophy 9. *Mol. Vis.* 16, 1549–1569.
- Gomez, N.M., Tamm, E.R., Straubeta, O., 2013. Role of bestrophin-1 in store-operated calcium entry in retinal pigment epithelium. *Pflügers Arch.* 465, 481–495.
- Gonzalez-Cordero, A., West, E.L., Pearson, R.A., Duran, Y., Carvalho, L.S., Chu, C.J., Naeem, A., Blackford, S.J., Georgiadis, A., Lakowski, J., Hubank, M., Smith, A.J., Bainbridge, J.W., Sowden, J.C., Ali, R.R., 2013. Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. *Nat. Biotechnol.* 31, 741–747.
- Gonzalez-Fernandez, F., Dann, C.A., Garlipp, M.A., 2011. Novel strategy for subretinal delivery in *Xenopus*. *Mol. Vis.* 17, 2956–2969.
- Gopalakrishna, K.N., Doddapaneni, K., Boyd, K.K., Masuho, I., Martemyanov, K.A., Artemyev, N.O., 2011. Interaction of transducin with uncoordinated 119 protein (UNC119): implications for the model of transducin trafficking in rod photoreceptors. *J. Biol. Chem.* 286, 28954–28962.
- Graf, C., Niwa, S., Muller, M., Kinzel, B., Bornancin, F., 2008. Wild-type levels of ceramide and ceramide-1-phosphate in the retina of ceramide kinase-like-deficient mice. *Biochem. Biophys. Res. Commun.* 373, 159–163.
- Grau, T., Artemyev, N.O., Rosenberg, T., Dollfus, H., Haugen, O.H., Cumhur Sener, E., Jurklics, B., Andreasson, S., Kernstock, C., Larsen, M., Zrenner, E., Wissinger, B., Kohl, S., 2011. Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia. *Hum. Mol. Genet.* 20, 719–730.
- Gregory-Evans, K., Kelsell, R.E., Gregory-Evans, C.Y., Downes, S.M., Fitzke, F.W., Holder, G.E., Simunovic, M., Mollon, J.D., Taylor, R., Hunt, D.M., Bird, A.C., Moore, A.T., 2000. Autosomal dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase. *Ophthalmology* 107, 55–61.
- Gregory, C.Y., Evans, K., Wijesuriya, S.D., Kermani, S., Jay, M.R., Plant, C., Cox, N., Bird, A.C., Bhattacharya, S.S., 1996. The gene responsible for autosomal dominant Doyny's honeycomb retinal dystrophy (DHRD) maps to chromosome 2p16. *Hum. Mol. Genet.* 5, 1055–1059.
- Guziewicz, K.E., Zangerl, B., Komaromy, A.M., Iwabe, S., Chiodo, V.A., Boye, S.L., Hauswirth, W.W., Beltran, W.A., Aguirre, G.D., 2013. Recombinant AAV-mediated BEST1 Transfer to the retinal pigment epithelium: analysis of serotype-dependent retinal effects. *PLoS One* 8, e75666.
- Haider, N.B., Jacobson, S.G., Cideciyan, A.V., Swiderski, R., Streib, L.M., Searby, C., Beck, G., Hockey, R., Hanna, D.B., Gorman, S., Duhl, D., Carmi, R., Bennett, J., Weleber, R.G., Fishman, G.A., Wright, A.F., Stone, E.M., Sheffield, V.C., 2000. Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. *Nat. Genet.* 24, 127–131.
- Hamel, C.P., 2007. Cone rod dystrophies. *Orphanet J. Rare Dis.* 2, 7.
- Han, Z., Conley, S.M., Makkia, R.S., Cooper, M.J., Naash, M.I., 2012. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. *J. Clin. Investig.* 122, 3221–3226.
- Hannun, Y.A., Obeid, L.M., 2008. Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat. Rev. Mol. Cell Biol.* 9, 139–150.

- Hawes, N.L., Wang, X., Hurd, R.E., Wang, J., Davisson, M.T., Nusinowitz, S., Heckenlively, J.R., Chang, B., 2006. A point mutation in the *Cnga3* gene causes cone photoreceptor function loss (*cpfl5*) in mice. *Investig. Ophthalmol. Vis. Sci.* 47, 4579.
- Hayward, C., Shu, X., Cideciyan, A.V., Lennon, A., Barran, P., Zarepari, S., Sawyer, L., Hendry, G., Dhillon, B., Milam, A.H., Luthert, P.J., Swaroop, A., Hastie, N.D., Jacobson, S.G., Wright, A.F., 2003. Mutation in a short-chain collagen gene, *CTRP5*, results in extracellular deposit formation in late-onset retinal degeneration: a genetic model for age-related macular degeneration. *Hum. Mol. Genet.* 12, 2657–2667.
- Hellsten, U., Harland, R.M., Gilchrist, M.J., Hendrix, D., Jurka, J., Kapitonov, V., Ovcharenko, I., Putnam, N.H., Shu, S., Taher, L., Blitz, I.L., Blumberg, B., Dichmann, D.S., Dubchak, I., Amaya, E., Detter, J.C., Fletcher, R., Gerhard, D.S., Goodstein, D., Graves, T., Grigoriev, I.V., Grimwood, J., Kawashima, T., Lindquist, E., Lucas, S.M., Mead, P.E., Mitros, T., Ogino, H., Ohta, Y., Poliakov, A.V., Pollet, N., Robert, J., Salamov, A., Sater, A.K., Schmutz, J., Terry, A., Vize, P.D., Warren, W.C., Wells, D., Wills, A., Wilson, R.K., Zimmerman, L.B., Zorn, A.M., Grainger, R., Grammer, T., Khokha, M.K., Richardson, P.M., Rokhsar, D.S., 2010. The genome of the Western clawed frog *Xenopus tropicalis*. *Science* 328, 633–636.
- Homma, K., Okamoto, S., Mandai, M., Gotoh, N., Rajasimha, H.K., Chang, Y.S., Chen, S., Li, W., Cogliati, T., Swaroop, A., Takahashi, M., 2013. Developing rods transplanted into the degenerating retina of *Crx*-knockout mice exhibit neural activity similar to native photoreceptors. *Stem Cells* 31, 1149–1159.
- Hong, D.H., Pawlyk, B.S., Shang, J., Sandberg, M.A., Berson, E.L., Li, T., 2000. A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). *Proc. Natl. Acad. Sci. U. S. A.* 97, 3649–3654.
- Howes, K.A., Pennesi, M.E., Sokal, I., Church-Kopish, J., Schmidt, B., Margolis, D., Frederick, J.M., Rieke, F., Palczewski, K., Wu, S.M., Detwiler, P.B., Baehr, W., 2002. *GCAP1* rescues rod photoreceptor response in *GCAP1/GCAP2* knockout mice. *EMBO J.* 21, 1545–1554.
- Hu, J., Zhong, C., Ding, C., Chi, Q., Walz, A., Mombaerts, P., Matsunami, H., Luo, M., 2007. Detection of near-atmospheric concentrations of CO₂ by an olfactory subsystem in the mouse. *Science* 317, 953–957.
- Huang, L., Zhang, Q., Li, S., Guan, L., Xiao, X., Zhang, J., Jia, X., Sun, W., Zhu, Z., Gao, Y., Yin, Y., Wang, P., Guo, X., Wang, J., Zhang, Q., 2013. Exome sequencing of 47 Chinese families with cone-rod dystrophy: mutations in 25 known causative genes. *PLoS One* 8, e65546.
- Huang, W.C., Wright, A.F., Roman, A.J., Cideciyan, A.V., Mansour, F.D., Gewaily, D.Y., Schwartz, S.B., Sadigh, S., Limberis, M.P., Bell, P., Wilson, J.M., Swaroop, A., Jacobson, S.G., 2012. RPGR-associated retinal degeneration in human X-linked RP and a murine model. *Investig. Ophthalmol. Vis. Sci.* 53, 5594–5608.
- Hunt, D.M., Buch, P., Michaelides, M., 2010. Guanylate cyclases and associated activator proteins in retinal disease. *Mol. Cell. Biochem.* 334, 157–168.
- Iannaccone, A., Wang, X., Jablonski, M.M., Kuo, S.F., Baldi, A., Cosgrove, D., Morton, C.C., Swaroop, A., 2004. Increasing evidence for syndromic phenotypes associated with RPGR mutations. *Am. J. Ophthalmol.* 137, 785–786 author reply 786.
- Ikeda, S., Shiva, N., Ikeda, A., Smith, R.S., Nusinowitz, S., Yan, G., Lin, T.R., Chu, S., Heckenlively, J.R., North, M.A., Naggert, J.K., Nishina, P.M., Duyao, M.P., 2000. Retinal degeneration but not obesity is observed in null mutants of the tubby-like protein 1 gene. *Hum. Mol. Genet.* 9, 155–163.
- Insinna, C., Besharse, J.C., 2008. Intraflagellar transport and the sensory outer segment of vertebrate photoreceptors. *Dev. Dyn.* 237, 1982–1992.
- Ishiba, Y., Higashide, T., Mori, N., Kobayashi, A., Kubota, S., McLaren, M.J., Satoh, H., Wong, F., Inana, G., 2007. Targeted inactivation of synaptic HRG4 (*UNC119*) causes dysfunction in the distal photoreceptor and slow retinal degeneration, revealing a new function. *Exp. Eye Res.* 84, 473–485.
- Jalili, I.K., 2010. Cone-rod dystrophy and amelogenesis imperfecta (Jalili syndrome): phenotypes and environs. *Eye* 24, 1659–1668.
- James-Zorn, C., Ponferrada, V.G., Jarabek, C.J., Burns, K.A., Segerdell, E.J., Lee, J., Snyder, K., Bhattacharyya, B., Karpinka, J.B., Fortriede, J., Bowes, J.B., Zorn, A.M., Vize, P.D., 2013. Xenbase: expansion and updates of the *Xenopus* model organism database. *Nucleic Acids Res.* 41, D865–D870.
- Janssen, A., Hoellenriegel, J., Fogarasi, M., Schrewe, H., Seeliger, M., Tamm, E., Ohlmann, A., May, C.A., Weber, B.H., Stohr, H., 2008. Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloproteinase-3. *Investig. Ophthalmol. Vis. Sci.* 49, 2812–2822.
- Jiang, L., Zhang, H., Dizhoor, A.M., Boye, S.E., Hauswirth, W.W., Frederick, J.M., Baehr, W., 2011. Long-term RNA interference gene therapy in a dominant retinitis pigmentosa mouse model. *Proc. Natl. Acad. Sci. U. S. A.* 108, 18476–18481.
- Jobling, A.I., Vessey, K.A., Waugh, M., Mills, S.A., Fletcher, E.L., 2013. A naturally occurring mouse model of achromatopsia: characterization of the mutation in cone transducin and subsequent retinal phenotype. *Investig. Ophthalmol. Vis. Sci.* 54, 3350–3359.
- Johnson, K.R., Longo-Guess, C., Gagnon, L.H., Yu, H., Zheng, Q.Y., 2008. A locus on distal chromosome 11 (*ahl8*) and its interaction with *Cdh23* *ahl* underlie the early onset, age-related hearing loss of *DBA/2J* mice. *Genomics* 92, 219–225.
- Johnson, S., Michaelides, M., Aligianis, I.A., Ainsworth, J.R., Mollon, J.D., Maher, E.R., Moore, A.T., Hunt, D.M., 2004. Achromatopsia caused by novel mutations in both *CNG3* and *CNGB3*. *J. Med. Genet.* 41, e20.
- Kaesler, P.S., Kwon, H.B., Chiu, C.Q., Deng, L., Castillo, P.E., Sudhof, T.C., 2008. *RIM1alpha* and *RIM1beta* are synthesized from distinct promoters of the *RIM1* gene to mediate differential but overlapping synaptic functions. *J. Neurosci.* 28, 13435–13447.
- Kajiwar, K., Berson, E., Dryja, T., 1994. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and *ROM1* loci. *Science* 264, 1604–1608.
- Kawamoto, H., Yasuda, O., Suzuki, T., Ozaki, T., Yotsui, T., Higuchi, M., Rakugi, H., Fukuo, K., Ogihara, T., Maeda, N., 2006. Tissue inhibitor of metalloproteinase-3 plays important roles in the kidney following unilateral ureteral obstruction. *Hypertens. Res.* 29, 285–294.
- Kaylor, J.J., Yuan, Q., Cook, J., Sarfare, S., Makshanoff, J., Miu, A., Kim, A., Kim, P., Habib, S., Roybal, C.N., Xu, T., Nusinowitz, S., Travis, G.H., 2013. Identification of *DES1* as a vitamin A isomerase in Muller glial cells of the retina. *Nat. Chem. Biol.* 9, 30–36.
- Kelsell, R.E., Gregory-Evans, K., Payne, A.M., Perrault, I., Kaplan, J., Yang, R.B., Garbers, D.L., Bird, A.C., Moore, A.T., Hunt, D.M., 1998. Mutations in the retinal guanylate cyclase (*RETGC-1*) gene in dominant cone-rod dystrophy. *Hum. Mol. Genet.* 7, 1179–1184.
- Kirschman, L.T., Kolandaivelu, S., Frederick, J.M., Dang, L., Goldberg, A.F., Baehr, W., Ramamurthy, V., 2010. The Leber congenital amaurosis protein, *AIPL1*, is needed for the viability and functioning of cone photoreceptor cells. *Hum. Mol. Genet.* 19, 1076–1087.
- Kitiratschky, V.B., Glockner, C.J., Kohl, S., 2011. Mutation screening of the *GUCA1B* gene in patients with autosomal dominant cone and cone rod dystrophy. *Ophthalmic Genet.* 32, 151–155.
- Kitiratschky, V.B., Wilke, R., Renner, A.B., Kellner, U., Vadala, M., Birch, D.G., Wissinger, B., Zrenner, E., Kohl, S., 2008. Mutation analysis identifies *GUCY2D* as the major gene responsible for autosomal dominant progressive cone degeneration. *Investig. Ophthalmol. Vis. Sci.* 49, 5015–5023.
- Klenotic, P.A., Munier, F.L., Marmorstein, L.Y., Anand-Apte, B., 2004. Tissue inhibitor of metalloproteinases-3 (*TIMP-3*) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (*EFEMP1*). Implications for macular degenerations. *J. Biol. Chem.* 279, 30469–30473.
- Kobayashi, A., Higashide, T., Hamasaki, D., Kubota, S., Sakuma, H., An, W., Fujimaki, T., McLaren, M.J., Weleber, R.G., Inana, G., 2000. *HRG4* (*UNC119*) mutation found in cone-rod dystrophy causes retinal degeneration in a transgenic model. *Investig. Ophthalmol. Vis. Sci.* 41, 3268–3277.
- Koenekoop, R.K., 2004. An overview of Leber congenital amaurosis: a model to understand human retinal development. *Surv. Ophthalmol.* 49, 379–398.
- Koenekoop, R.K., Loyer, M., Hand, C.K., Al Mahdi, H., Dembinska, O., Beneish, R., Racine, J., Rouleau, G.A., 2003. Novel RPGR mutations with distinct retinitis pigmentosa phenotypes in French-Canadian families. *Am. J. Ophthalmol.* 136, 678–687.
- Koepfen, K., Reuter, P., Kohl, S., Baumann, B., Ladewig, T., Wissinger, B., 2008. Functional analysis of human *CNGA3* mutations associated with colour blindness suggests impaired surface expression of channel mutants *A3(R427C)* and *A3(R563C)*. *Eur. J. Neurosci.* 27, 2391–2401.
- Kohl, S., Baumann, B., Broghammer, M., Jagle, H., Sieving, P., Kellner, U., Spegal, R., Anastasi, M., Zrenner, E., Sharpe, L.T., Wissinger, B., 2000. Mutations in the *CNGB3* gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (*ACHM3*) linked to chromosome 8q21. *Hum. Mol. Genet.* 9, 2107–2116.
- Kohl, S., Baumann, B., Rosenberg, T., Kellner, U., Lorenz, B., Vadala, M., Jacobson, S.G., Wissinger, B., 2002. Mutations in the cone photoreceptor G-protein alpha-subunit gene *GNAT2* in patients with achromatopsia. *Am. J. Hum. Genet.* 71, 422–425.
- Kohl, S., Coppieters, F., Meire, F., Schaich, S., Roosing, S., Brennenstuhl, C., Bolz, S., van Genderen, M.M., Riemsdijk, F.C., European Retinal Disease C., Lukowski, R., den Hollander, A.I., Cremers, F.P., De Baere, E., Hoyng, C.B., Wissinger, B., 2012. A nonsense mutation in *PDE6H* causes autosomal-recessive incomplete achromatopsia. *Am. J. Hum. Genet.* 91, 527–532.
- Kohl, S., Marx, T., Giddings, I., Jagle, H., Jacobson, S.G., Apfelstedt-Sylla, E., Zrenner, E., Sharpe, L.T., Wissinger, B., 1998. Total colourblindness is caused by mutations in the gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation channel. *Nat. Genet.* 19, 257–259.
- Kohn, L., Kadzhaev, K., Burstedt, M.S., Haraldsson, S., Hallberg, B., Sandgren, O., Golovleva, I., 2007. Mutation in the *PYK2*-binding domain of *PITPNM3* causes autosomal dominant cone dystrophy (*CORD5*) in two Swedish families. *Eur. J. Hum. Genet.* 15, 664–671.
- Kolandaivelu, S., Huang, J., Hurley, J.B., Ramamurthy, V., 2009. *AIPL1*, a protein associated with childhood blindness, interacts with alpha-subunit of rod phosphodiesterase (*PDE6*) and is essential for its proper assembly. *J. Biol. Chem.* 284, 30853–30861.
- Kolandaivelu, S., Singh, R.K., Ramamurthy, V., 2013. *AIPL1*, a protein linked to blindness, is essential for the stability of enzymes mediating cGMP metabolism in cone photoreceptor cells. *Hum. Mol. Genet.* 23, 1002–1012.
- Komáromy, A.M., Alexander, J.J., Rowlan, J.S., Garcia, M.M., Chiodo, V.A., Kaya, A., Tanaka, J.C., Acland, G.M., Hauswirth, W.W., Aguirre, G.D., 2010. Gene therapy rescues cone function in congenital achromatopsia. *Hum. Mol. Genet.* 19, 2581–2593.
- Komáromy, A.M., Rowlan, J.S., Corr, A.T., Reinstein, S.L., Boye, S.L., Cooper, A.E., Gonzalez, A., Levy, B., Wen, R., Hauswirth, W.W., Beltran, W.A., Aguirre, G.D., 2013. Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage *CNGB3*-achromatopsia. *Mol. Ther.* 21, 1131–1141.
- Kong, J., Kim, S.R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqbal, S., Naylor, S., Sparrow, J.R., Gouras, P., Allikmets, R., 2008. Correction of

- the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. *Gene Ther.* 15, 1311–1320.
- Kostic, C., Lilloco, S.G., Crippa, S.V., Grandchamp, N., Pilet, H., Philippe, S., Lu, Z., King, T.J., Mallet, J., Sarkis, C., Arsenijevic, Y., Whitelaw, C.B., 2013. Rapid cohort generation and analysis of disease spectrum of large animal model of cone dystrophy. *PLoS One* 8, e71363.
- Kremer, H., Pinckers, A., van den Helm, B., Deutman, A.F., Ropers, H.H., Mariman, E.C., 1994. Localization of the gene for dominant cystoid macular dystrophy on chromosome 7p. *Hum. Mol. Genet.* 3, 299–302.
- Kropatsch, R., Petrasch-Parwez, E., Seelow, D., Schlichting, A., Gerding, W.M., Akkad, D.A., Epplen, J.T., Dekomien, G., 2010. Generalized progressive retinal atrophy in the Irish Glen of Imaal Terrier is associated with a deletion in the ADAM9 gene. *Mol. Cell. Probes* 24, 357–363.
- Ku, C.A., Chiodo, V.A., Boye, S.L., Goldberg, A.F., Li, T., Hauswirth, W.W., Ramamurthy, V., 2011. Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis. *Hum. Mol. Genet.* 20, 4569–4581.
- Kumanogoh, A., Shikina, T., Suzuki, K., Uematsu, S., Yukawa, K., Kashiwamura, S., Tsutsui, H., Yamamoto, M., Takamatsu, H., Ko-Mitamura, E.P., Takegahara, N., Marukawa, S., Ishida, I., Morishita, H., Prasad, D.V., Tamura, M., Mizui, M., Toyofuku, T., Akira, S., Takeda, K., Okabe, M., Kikutani, H., 2005. Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. *Immunity* 22, 305–316.
- Kumar, M., Keller, B., Makalou, N., Sutton, R.E., 2001. Systematic determination of the packaging limit of lentiviral vectors. *Hum. Gene Ther.* 12, 1893–1905.
- Kuznetsova, T., Zangerl, B., Aguirre, G.D., 2012. RPGRIP1 and cone-rod dystrophy in dogs. *Adv. Exp. Med. Biol.* 723, 321–328.
- Lambert, S.R., Kriss, A., Gresty, M., Benton, S., Taylor, D., 1989. Joubert syndrome. *Arch. Ophthalmol.* 107, 709–713.
- Leco, K.J., Waterhouse, P., Sanchez, O.H., Gowing, K.L., Poole, A.R., Wakeham, A., Mak, T.W., Khokha, R., 2001. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). *J. Clin. Invest.* 108, 817–829.
- Lefler, W.H., Wadsworth, J.A., Sidbury Jr., J.B., 1971. Hereditary macular degeneration and amino-aciduria. *Am. J. Ophthalmol.* 71, 224–230.
- Leinders-Zufall, T., Cockerham, R.E., Michalakakis, S., Biel, M., Garbers, D.L., Reed, R.R., Zufall, F., Munger, S.D., 2007. Contribution of the receptor guanylyl cyclase GC-D to chemosensory function in the olfactory epithelium. *Proc. Natl. Acad. Sci. U. S. A.* 104, 14507–14512.
- Lev, S., 2004. The role of the Nir/rdgB protein family in membrane trafficking and cytoskeleton remodeling. *Exp. Cell Res.* 297, 1–10.
- Lev, S., Hernandez, J., Martinez, R., Chen, A., Plozman, G., Schlessinger, J., 1999. Identification of a novel family of targets of PYK2 related to Drosophila retinal degeneration B (rdgB) protein. *Mol. Cell. Biol.* 19, 2278–2288.
- Lhériteau, E., Petit, L., Weber, M., Le Meur, G., Deschamps, J.Y., Libeau, L., Mendes-Madeira, A., Guihal, C., Francois, A., Guyon, R., Provost, N., Lemoine, F., Papal, S., El-Amraoui, A., Colle, M.A., Moullet, P., Rolling, F., 2013. Successful gene therapy in the RPGRIP1-deficient dog, a large model of cone-rod dystrophy. *Mol. Ther.* 22, 265–277.
- Li, W., Chen, Y., Cameron, D.J., Wang, C., Karan, G., Yang, Z., Zhao, Y., Pearson, E., Chen, H., Deng, C., Howes, K., Zhang, K., 2007. Elov14 haploinsufficiency does not induce early onset retinal degeneration in mice. *Vis. Res.* 47, 714–722.
- Li, Y., Ling, K., Hu, J., 2012. The emerging role of Arf/Arp small GTPases in cilia and ciliopathies. *J. Cell. Biochem.* 113, 2201–2207.
- Littink, K.W., Koenekoop, R.K., van den Born, L.I., Collin, R.W., Moruz, L., Veltman, J.A., Roosing, S., Zonneveld, M.N., Omar, A., Darvish, M., Lopez, I., Kroes, H.Y., van Genderen, M.M., Hoyng, C.B., Rohrschneider, K., van Schooneveld, M.J., Cremers, F.P., den Hollander, A.I., 2010. Homozygosity mapping in patients with cone-rod dystrophy: novel mutations and clinical characterizations. *Invest. Ophthalmol. Vis. Sci.* 51, 5943–5951.
- Liu, C., Varnum, M.D., 2005. Functional consequences of progressive cone dystrophy-associated mutations in the human cone photoreceptor cyclic nucleotide-gated channel CNGA3 subunit. *Am. J. Physiol. Cell Physiol.* 289, C187–C198.
- Liu, X., Bulgakov, O.V., Wen, X.H., Woodruff, M.L., Pawlyk, B., Yang, J., Fain, G.L., Sandberg, M.A., Makino, C.L., Li, T., 2004. AIPL1, the protein that is defective in Leber congenital amaurosis, is essential for the biosynthesis of retinal rod cGMP phosphodiesterase. *Proc. Natl. Acad. Sci. U. S. A.* 101, 13903–13908.
- MacLaren, R.E., Pearson, R.A., MacNeil, A., Douglas, R.H., Salt, T.E., Akimoto, M., Swaroop, A., Sowden, J.C., Ali, R.R., 2006. Retinal repair by transplantation of photoreceptor precursors. *Nature* 444, 203–207.
- Maeda, A., Maeda, T., Sun, W., Zhang, H., Baehr, W., Palczewski, K., 2007. Redundant and unique roles of retinol dehydrogenases in the mouse retina. *Proc. Natl. Acad. Sci. U. S. A.* 104, 19565–19570.
- Makino, C.L., Peshenko, I.V., Wen, X.H., Olshevskaya, E.V., Barrett, R., Dizhoor, A.M., 2008. A role for GCAP2 in regulating the photoresponse. Guanylyl cyclase activation and rod electrophysiology in GUCA1B knock-out mice. *J. Biol. Chem.* 283, 29135–29143.
- Manes, G., Meunier, I., Avila-Fernandez, A., Banfi, S., Le Meur, G., Zanlonghi, X., Corton, M., Simonelli, F., Brabet, P., Labesse, G., Audo, I., Mohand-Said, S., Zeitz, C., Sahel, J.A., Weber, M., Dollfus, H., Dhaenens, C.M., Allorge, D., De Baere, E., Koenekoop, R.K., Kohl, S., Cremers, F.P., Hollyfield, J.G., Senechal, A., Hebrard, M., Bocquet, B., Garcia, C.A., Hamel, C.P., 2013. Mutations in IMPG1 cause vitelliform macular dystrophies. *Am. J. Hum. Genet.* 93, 571–578.
- Mansergh, F., Orton, N.C., Vessey, J.P., Lalonde, M.R., Stell, W.K., Tremblay, F., Barnes, S., Rancourt, D.E., Bech-Hansen, N.T., 2005. Mutation of the calcium channel gene *Cacna1f* disrupts calcium signaling, synaptic transmission and cellular organization in mouse retina. *Hum. Mol. Genet.* 14, 3035–3046.
- Marmorstein, L.Y., McLaughlin, P.J., Peachey, N.S., Sasaki, T., Marmorstein, A.D., 2007. Formation and progression of sub-retinal pigment epithelium deposits in *Efemp1* mutation knock-in mice: a model for the early pathogenic course of macular degeneration. *Hum. Mol. Genet.* 16, 2423–2432.
- Marmorstein, L.Y., Munier, F.L., Arsenijevic, Y., Schorderet, D.F., McLaughlin, P.J., Chung, D., Traboulsi, E., Marmorstein, A.D., 2002. Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 99, 13067–13072.
- Marmorstein, L.Y., Wu, J., McLaughlin, P., Yocom, J., Karl, M.O., Neussert, R., Wimmers, S., Stanton, J.B., Gregg, R.G., Strauss, O., Peachey, N.S., Marmorstein, A.D., 2006. The light peak of the electroretinogram is dependent on voltage-gated calcium channels and antagonized by brestrophin (best-1). *J. Gen. Physiol.* 127, 577–589.
- Maron, B.J., Roberts, W.C., Arad, M., Haas, T.S., Spirito, P., Wright, G.B., Almquist, A.K., Baffa, J.M., Saul, J.P., Ho, C.Y., Seidman, J., Seidman, C.E., 2009. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. *JAMA* 301, 1253–1259.
- Marshall, J.D., Maffei, P., Collin, G.B., Naggert, J.K., 2011. Alström syndrome: genetics and clinical overview. *Curr. Genomics* 12, 225–235.
- Mata, N.L., Radu, R.A., Clemmons, R.C., Travis, G.H., 2002. Isomerization and oxidation of vitamin A in cone-dominant retinas: a novel pathway for visual-pigment regeneration in daylight. *Neuron* 36, 69–80.
- Mata, N.L., Weng, J., Travis, G.H., 2000. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 97, 7154–7159.
- Matveev, A.V., Fitzgerald, J.B., Xu, J., Malykhina, A.P., Rodgers, K.K., Ding, X.Q., 2010. The disease-causing mutations in the carboxyl terminus of the cone cyclic nucleotide-gated channel CNGA3 subunit alter the local secondary structure and interfere with the channel active conformational change. *Biochemistry* 49, 1628–1639.
- Maugeri, A., Klevering, B.J., Rohrschneider, K., Blankenagel, A., Brunner, H.G., Deutman, A.F., Hoyng, C.B., Cremers, F.P., 2000. Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal recessive cone-rod dystrophy. *Am. J. Hum. Genet.* 67, 960–966.
- Maugeri, A., van Driel, M.A., van de Pol, D.J., Klevering, B.J., van Haren, F.J., Tijmes, N., Bergen, A.A., Rohrschneider, K., Blankenagel, A., Pinckers, A.J., Dahl, N., Brunner, H.G., Deutman, A.F., Hoyng, C.B., Cremers, F.P., 1999. The 2588G→C mutation in the ABCR gene is a mild frequent founder mutation in the Western European population and allows the classification of ABCR mutations in patients with Stargardt disease. *Am. J. Hum. Genet.* 64, 1024–1035.
- McClements, M., Davies, W.I., Michaelides, M., Young, T., Neitz, M., MacLaren, R.E., Moore, A.T., Hunt, D.M., 2013. Variations in opsin coding sequences cause x-linked cone dysfunction syndrome with myopia and dichromacy. *Investig. Ophthalmol. Vis. Sci.* 54, 1361–1369.
- McLaughlin, P.J., Bakall, B., Choi, J., Liu, Z., Sasaki, T., Davis, E.C., Marmorstein, A.D., Marmorstein, L.Y., 2007. Lack of fibulin-3 causes early aging and herniation, but not macular degeneration in mice. *Hum. Mol. Genet.* 16, 3059–3070.
- McMahon, A., Butovich, I.A., Mata, N.L., Klein, M., Ritter 3rd, R., Richardson, J., Birch, D.G., Edwards, A.O., Kedziarski, W., 2007. Retinal pathology and skin barrier defect in mice carrying a Stargardt disease-3 mutation in elongase of very long chain fatty acids-4. *Mol. Vis.* 13, 258–272.
- McNally, N., Kenna, P.F., Rancourt, D., Ahmed, T., Stitt, A., Colledge, W.H., Lloyd, D.G., Palfi, A., O'Neill, B., Humphries, M.M., Humphries, P., Farrar, G.J., 2002. Murine model of autosomal dominant retinitis pigmentosa generated by targeted deletion at codon 307 of the rds-peripherin gene. *Hum. Mol. Genet.* 11, 1005–1016.
- Mears, A.J., Kondo, M., Swain, P.K., Takada, Y., Bush, R.A., Saunders, T.L., Sieving, P.A., Swaroop, A., 2001. Nrl is required for rod photoreceptor development. *Nat. Genet.* 29, 447–452.
- Mekala, S.R., Vauhini, V., Nagarajan, U., Maddileti, S., Gaddipati, S., Mariappan, I., 2013. Derivation, characterization and retinal differentiation of induced pluripotent stem cells. *J. Biosci.* 38, 123–134.
- Mendez, A., Burns, M.E., Sokal, I., Dizhoor, A.M., Baehr, W., Palczewski, K., Baylor, D.A., Chen, J., 2001. Role of guanylate cyclase-activating proteins (GCAPs) in setting the flash sensitivity of rod photoreceptors. *Proc. Natl. Acad. Sci. U. S. A.* 98, 9948–9953.
- Mendez, A., Chen, J., 2002. Mouse models to study GCAP functions in intact photoreceptors. *Adv. Exp. Med. Biol.* 514, 361–388.
- Menotti-Raymond, M., Deckman, K.H., David, V., Myrkalov, J., O'Brien, S.J., Narfstrom, K., 2010. Mutation discovered in a feline model of human congenital retinal blinding disease. *Investig. Ophthalmol. Vis. Sci.* 51, 2852–2859.
- Michaelides, M., Hardcastle, A.J., Hunt, D.M., Moore, A.T., 2006. Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis. *Surv. Ophthalmol.* 51, 232–258.
- Michaelides, M., Holder, G.E., Bradshaw, K., Hunt, D.M., Mollon, J.D., Moore, A.T., 2004a. Oligocone trichromacy: a rare and unusual cone dysfunction syndrome. *Br. J. Ophthalmol.* 88, 497–500.
- Michaelides, M., Holder, G.E., Hunt, D.M., Fitzke, F.W., Bird, A.C., Moore, A.T., 2005a. A detailed study of the phenotype of an autosomal dominant cone-rod dystrophy (CORD7) associated with mutation in the gene for RIMI. *Br. J. Ophthalmol.* 89, 198–206.

- Michaelides, M., Hunt, D.M., Moore, A.T., 2004b. The cone dysfunction syndromes. *Br. J. Ophthalmol.* 88, 291–297.
- Michaelides, M., Johnson, S., Bradshaw, K., Holder, G.E., Simunovic, M.P., Mollon, J.D., Moore, A.T., Hunt, D.M., 2005b. X-linked cone dysfunction syndrome with myopia and protanopia. *Ophthalmology* 112, 1448–1454.
- Michaelides, M., Johnson, S., Tekriwal, A.K., Holder, G.E., Bellmann, C., Kinning, E., Woodruff, G., Trembath, R.C., Hunt, D.M., Moore, A.T., 2003. An early-onset autosomal dominant macular dystrophy (MCDR3) resembling North Carolina macular dystrophy maps to chromosome 5. *Investig. Ophthalmol. Vis. Sci.* 44, 2178–2183.
- Michalakos, S., Geiger, H., Haverkamp, S., Hofmann, F., Gerstner, A., Biel, M., 2005. Impaired opsin targeting and cone photoreceptor migration in the retina of mice lacking the cyclic nucleotide-gated channel CNGA3. *Investig. Ophthalmol. Vis. Sci.* 46, 1516–1524.
- Michalakos, S., Muhlfriedel, R., Tanimoto, N., Krishnamoorthy, V., Koch, S., Fischer, M.D., Becirovic, E., Bai, L., Huber, G., Beck, S.C., Fahl, E., Buning, H., Paquet-Durand, F., Zong, X., Gollisch, T., Biel, M., Seeliger, M.W., 2010. Restoration of cone vision in the CNGA3^{-/-} mouse model of congenital complete lack of cone photoreceptor function. *Mol. Ther.* 18, 2057–2063.
- Michalakos, S., Muhlfriedel, R., Tanimoto, N., Krishnamoorthy, V., Koch, S., Fischer, M.D., Becirovic, E., Bai, L., Huber, G., Beck, S.C., Fahl, E., Buning, H., Schmidt, J., Zong, X., Gollisch, T., Biel, M., Seeliger, M.W., 2012. Gene therapy restores missing cone-mediated vision in the CNGA3^{-/-} mouse model of achromatopsia. *Adv. Exp. Med. Biol.* 723, 183–189.
- Miki, T., Kiyonaka, S., Urie, Y., De Waard, M., Wakamori, M., Beedle, A.M., Campbell, K.P., Mori, Y., 2007. Mutation associated with an autosomal dominant cone-rod dystrophy CORD7 modifies RIM1-mediated modulation of voltage-dependent Ca²⁺ channels. *Channels* 1, 144–147.
- Milligan, S.C., Alb Jr., J.G., Elagina, R.B., Bankaitis, V.A., Hyde, D.R., 1997. The phosphatidylinositol transfer protein domain of Drosophila retinal degeneration B protein is essential for photoreceptor cell survival and recovery from light stimulation. *J. Cell Biol.* 139, 351–363.
- Miyazono, S., Shimauchi-Matsukawa, Y., Tachibanaki, S., Kawamura, S., 2008. Highly efficient retinal metabolism in cones. *Proc. Natl. Acad. Sci. U. S. A.* 105, 16051–16056.
- Molday, L.L., Rabin, A.R., Molday, R.S., 2000. ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy. *Nat. Genet.* 25, 257–258.
- Moritz, O.L., Tam, B.M., Knox, B.E., Papermaster, D.S., 1999. Fluorescent photoreceptors of transgenic *Xenopus laevis* imaged in vivo by two microscopy techniques. *Investig. Ophthalmol. Vis. Sci.* 40, 3276–3280.
- Mussolino, C., Della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., Crasta, M., Giunti, M., Villani, E., Lavitrano, M., Bacci, M.L., Ratiglia, R., Simonelli, F., Auricchio, A., Surace, E.M., 2011. AAV-mediated photoreceptor transduction of the pig cone-enriched retina. *Gene Ther.* 18, 637–645.
- Nakazawa, M., Kikawa, E., Chida, Y., Wada, Y., Shiono, T., Tamai, M., 1996a. Autosomal dominant cone-rod dystrophy associated with mutations in codon 244 (Asn244His) and codon 184 (Tyr184Ser) of the peripherin/RDS gene. *Arch. Ophthalmol.* 114, 72–78.
- Nakazawa, M., Naoi, N., Wada, Y., Nakazaki, S., Maruiwa, F., Sawada, A., Tamai, M., 1996b. Autosomal dominant cone-rod dystrophy associated with a Val200Glu mutation of the peripherin/RDS gene. *Retina* 16, 405–410.
- Nathans, J., Davenport, C.M., Maumenee, I.H., Lewis, R.A., Hejtmancik, J.F., Litt, M., Lovrien, E., Weleber, R., Bachynski, B., Zwas, F., Klingaman, R., Fishman, G., 1989. Molecular genetics of human blue cone monochromacy. *Science* 245, 831–838.
- Nevet, M.J., Vekslin, S., Dizhoor, A.M., Olshevskaya, E.V., Tidhar, R., Futerman, A.H., Ben-Yosef, T., 2012. Ceramide kinase-like (CERKL) interacts with neuronal calcium sensor proteins in the retina in a cation-dependent manner. *Investig. Ophthalmol. Vis. Sci.* 53, 4565–4574.
- Nikonov, S.S., Daniele, L.L., Zhu, X., Craft, C.M., Swaroop, A., Pugh Jr., E.N., 2005. Photoreceptors of Nr1^{-/-} mice coexpress functional S- and M-cone opsins having distinct inactivation mechanisms. *J. Gen. Physiol.* 125, 287–304.
- Nishide, K., Nakatani, Y., Kiyonari, H., Kondo, T., 2009. Glioblastoma formation from cell population depleted of Prominin1-expressing cells. *PLoS One* 4, e6869.
- Nishiguchi, K.M., Tearle, R.G., Liu, Y.P., Oh, E.C., Miyake, N., Benaglio, P., Harper, S., Koskiniemi-Kuendig, H., Venturini, G., Sharon, D., Koeneke, R.K., Nakamura, M., Kondo, M., Ueno, S., Yasuma, T.R., Beckmann, J.S., Ikegawa, S., Matsumoto, N., Terasaki, H., Berson, E.L., Katsanis, N., Rivolta, C., 2013. Whole genome sequencing in patients with retinitis pigmentosa reveals pathogenic DNA structural changes and NEK2 as a new disease gene. *Proc. Natl. Acad. Sci. U. S. A.* 110, 16139–16144.
- Noble, K.G., Carr, R.E., 1979. Stargardt's disease and fundus flavimaculatus. *Arch. Ophthalmol.* 97, 1281–1285.
- Nystuen, A.M., Sachs, A.J., Yuan, Y., Heuermann, L., Haider, N.B., 2008. A novel mutation in Prph2, a gene regulated by Nr2e3, causes retinal degeneration and outer-segment defects similar to Nr2e3 (rd7/rd7) retinas. *Mamm. Genome* 19, 623–633.
- Oh, E.C., Khan, N., Novelli, E., Khanna, H., Strettoi, E., Swaroop, A., 2007. Transformation of cone precursors to functional rod photoreceptors by bZIP transcription factor NRL. *Proc. Natl. Acad. Sci. U. S. A.* 104, 1679–1684.
- Ottschytch, N., Raes, A., Van Hooricck, D., Snyders, D.J., 2002. Obligatory heterotrimerization of three previously uncharacterized Kv channel alpha-subunits identified in the human genome. *Proc. Natl. Acad. Sci. U. S. A.* 99, 7986–7991.
- Pang, J.J., Alexander, J., Lei, B., Deng, W., Zhang, K., Li, Q., Chang, B., Hauswirth, W.W., 2010. Achromatopsia as a potential candidate for gene therapy. *Adv. Exp. Med. Biol.* 664, 639–646.
- Pang, J.J., Deng, W.T., Dai, X., Lei, B., Everhart, D., Umino, Y., Li, J., Zhang, K., Mao, S., Boye, S.L., Liu, L., Chiodo, V.A., Liu, X., Shi, W., Tao, Y., Chang, B., Hauswirth, W.W., 2012. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. *PLoS One* 7, e35250.
- Park, S.J., Woo, S.J., Park, K.H., Hwang, J.M., Chung, H., 2010. Morphologic photoreceptor abnormality in occult macular dystrophy on spectral-domain optical coherence tomography. *Investig. Ophthalmol. Vis. Sci.* 51, 3673–3679.
- Parry, D.A., Toomes, C., Bida, L., Danciger, M., Towns, K.V., McKibbin, M., Jacobson, S.G., Logan, C.V., Ali, M., Bond, J., Chance, R., Swendeman, S., Daniele, L.L., Springell, K., Adams, M., Johnson, C.A., Booth, A.P., Jafri, H., Rashid, Y., Banin, E., Strom, T.M., Farber, D.B., Sharon, D., Blobel, C.P., Pugh Jr., E.N., Pierce, E.A., Inglehearn, C.F., 2009. Loss of the metalloprotease ADAM9 leads to cone-rod dystrophy in humans and retinal degeneration in mice. *Am. J. Hum. Genet.* 84, 683–691.
- Pawlyk, B.S., Bulgakov, O.V., Liu, X., Xu, X., Adamian, M., Sun, X., Khani, S.C., Berson, E.L., Sandberg, M.A., Li, T., 2010. Replacement gene therapy with a human RGRIP1 sequence slows photoreceptor degeneration in a murine model of Leber congenital amaurosis. *Hum. Gene Ther.* 21, 993–1004.
- Payne, A.M., Morris, A.G., Downes, S.M., Johnson, S., Bird, A.C., Moore, A.T., Bhattacharya, S.S., Hunt, D.M., 2001. Clustering and frequency of mutations in the retinal guanylate cyclase (GUCY2D) gene in patients with dominant cone-rod dystrophies. *J. Med. Genet.* 38, 611–614.
- Pearson, R.A., Barber, A.C., West, E.L., MacLaren, R.E., Duran, Y., Bainbridge, J.W., Sowden, J.C., Ali, R.R., 2010. Targeted disruption of outer limiting membrane junctional proteins (Crb1 and ZO-1) increases integration of transplanted photoreceptor precursors into the adult wild-type and degenerating retina. *Cell Transpl.* 19, 487–503.
- Poloschek, C.M., Bach, M., Lagreze, W.A., Glaus, E., Lemke, J.R., Berger, W., Neidhardt, J., 2010. ABCA4 and ROM1: implications for modification of the PRPH2-associated macular dystrophy phenotype. *Investig. Ophthalmol. Vis. Sci.* 51, 4253–4265.
- Prall, F.R., Drack, A., Taylor, M., Ku, L., Olson, J.L., Gregory, D., Mestroni, L., Mandava, N., 2006. Ophthalmic manifestations of Danon disease. *Ophthalmology* 113, 1010–1013.
- Quazi, F., Lenevich, S., Molday, R.S., 2012. ABCA4 is an N-retinylidene-phosphatidylethanolamine and phosphatidylethanolamine importer. *Nat. Commun.* 3, 925.
- Radu, R.A., Mata, N.L., Bagla, A., Travis, G.H., 2004. Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt's macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 101, 5928–5933.
- Ramamurthy, V., Niemi, G.A., Reh, T.A., Hurley, J.B., 2004. Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase. *Proc. Natl. Acad. Sci. U. S. A.* 101, 13897–13902.
- Rattner, A., Smallwood, P.M., Williams, J., Cooke, C., Savchenko, A., Lyubarsky, A., Pugh, E.N., Nathans, J., 2001. A photoreceptor-specific cadherin is essential for the structural integrity of the outer segment and for photoreceptor survival. *Neuron* 32, 775–786.
- Raz-Prag, D., Ayyagari, R., Fariss, R.N., Mandal, M.N., Vasireddy, V., Majchrzak, S., Webber, A.L., Bush, R.A., Salem Jr., N., Petrukhin, K., Sieving, P.A., 2006. Haploinsufficiency is not the key mechanism of pathogenesis in a heterozygous Elov14 knockout mouse model of STGD3 disease. *Investig. Ophthalmol. Vis. Sci.* 47, 3603–3611.
- Reicher, S., Seroussi, E., Gootwine, E., 2010. A mutation in gene CNGA3 is associated with day blindness in sheep. *Genomics* 95, 101–104.
- Renner, A.B., Fiebig, B.S., Weber, B.H., Wissinger, B., Andreasson, S., Gal, A., Cropp, E., Kohl, S., Kellner, U., 2009. Phenotypic variability and long-term follow-up of patients with known and novel PRPH2/RDS gene mutations. *Am. J. Ophthalmol.* 147, 518, 530 e511.
- Reuter, P., Koeppen, K., Ladewig, T., Kohl, S., Baumann, B., Wissinger, B., Achromatopsia Clinical Study, G., 2008. Mutations in CNGA3 impair trafficking or function of cone cyclic nucleotide-gated channels, resulting in achromatopsia. *Hum. Mutat.* 29, 1228–1236.
- Rice, D.S., Huang, W., Jones, H.A., Hansen, G., Ye, G.L., Xu, N., Wilson, E.A., Troughton, K., Vaddi, K., Newton, R.C., Zambrowicz, B.P., Sands, A.T., 2004. Severe retinal degeneration associated with disruption of semaphorin 4A. *Investig. Ophthalmol. Vis. Sci.* 45, 2767–2777.
- Riera, M., Burguera, D., Garcia-Fernandez, J., Gonzalez-Duarte, R., 2013. CERKL knockdown causes retinal degeneration in zebrafish. *PLoS One* 8, e64048.
- Robson, A.G., Webster, A.R., Michaelides, M., Downes, S.M., Cowing, J.A., Hunt, D.M., Moore, A.T., Holder, G.E., 2010. "Cone dystrophy with supernormal rod electroretinogram": a comprehensive genotype/phenotype study including fundus autofluorescence and extensive electrophysiology. *Retina* 30, 51–62.
- Roduit, R., Escher, P., Schorderet, D.F., 2009. Mutations in the DNA-binding domain of NR2E3 affect in vivo dimerization and interaction with CRX. *PLoS One* 4, e7379.
- Roosing, S., Rohrschneider, K., Beryozkin, A., Sharon, D., Weisschuh, N., Staller, J., Kohl, S., Zeling, L., Peters, T.A., Neveling, K., Strom, T.M., European Retinal Disease C., van den Born, L.I., Hoyng, C.B., Klaver, C.C., Roepman, R., Wissinger, B., Banin, E., Cremers, F.P., den Hollander, A.I., 2013. Mutations in RAB28, encoding a farnesylated small GTPase, are associated with autosomal-recessive cone-rod dystrophy. *Am. J. Hum. Genet.* 93, 110–117.

- Rosenberg, T., Roos, B., Johnsen, T., Bech, N., Scheetz, T.E., Larsen, M., Stone, E.M., Fingert, J.H., 2010. Clinical and genetic characterization of a Danish family with North Carolina macular dystrophy. *Mol. Vis.* 16, 2659–2668.
- Rotenstreich, Y., Fishman, G.A., Anderson, R.J., 2003. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. *Ophthalmology* 110, 1151–1158.
- Ruether, K., Grosse, J., Matthiessen, E., Hoffmann, K., Hartmann, C., 2000. Abnormalities of the photoreceptor-bipolar cell synapse in a substrain of C57BL/10 mice. *Investig. Ophthalmol. Vis. Sci.* 41, 4039–4047.
- Sarra, G.M., Stephens, C., de Alwis, M., Bainbridge, J.W., Smith, A.J., Thrasher, A.J., Ali, R.R., 2001. Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina. *Hum. Mol. Genet.* 10, 2353–2361.
- Schoch, S., Castillo, P.E., Jo, T., Mukherjee, K., Geppert, M., Wang, Y., Schmitz, F., Malenka, R.C., Sudhof, T.C., 2002. RIM1alpha forms a protein scaffold for regulating neurotransmitter release at the active zone. *Nature* 415, 321–326.
- Schoch, S., Mittelstaedt, T., Kaeser, P.S., Padgett, D., Feldmann, N., Chevaleyre, V., Castillo, P.E., Hammer, R.E., Han, W., Schmitz, F., Lin, W., Sudhof, T.C., 2006. Redundant functions of RIM1alpha and RIM2alpha in Ca(2+)-triggered neurotransmitter release. *EMBO J.* 25, 5852–5863.
- Scholl, H.P., Kremers, J., 2003. Alterations of L- and M-cone driven ERGs in cone and cone-rod dystrophies. *Vis. Res.* 43, 2333–2344.
- Schön, C., Biel, M., Michalakis, S., 2013. Gene replacement therapy for retinal CNG channelopathies. *Mol. Genet. Genomics* 288, 459–467.
- Schorderet, D.F., Escher, P., 2009. NR2E3 mutations in enhanced S-cone sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP). *Hum. Mutat.* 30, 1475–1485.
- Schworm, H.D., Ulbig, M.W., Hoops, J., Rudolph, G., Weber, B.H., Ehrh, O., Boergen, K.P., 1998. North Carolina macular dystrophy. Hereditary macular disease with good functional prognosis. *Dev. Ophthalmol.* 95, 13–18.
- Shmelkov, S.V., Butler, J.M., Hooper, A.T., Hormigo, A., Kushner, J., Milde, T., St Clair, R., Baljevic, M., White, I., Jin, D.K., Chadburn, A., Murphy, A.J., Valenzuela, D.M., Gale, N.W., Thurston, G., Yancopoulos, G.D., D'Angelica, M., Kemeny, N., Lyden, D., Rafii, S., 2008. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. *J. Clin. Invest.* 118, 2111–2120.
- Shu, X., Luhmann, U.F., Aleman, T.S., Barker, S.E., Lennon, A., Tulloch, B., Chen, M., Xu, H., Jacobson, S.G., Ali, R., Wright, A.F., 2011. Characterisation of a C1qtnf5 Ser163Arg knock-in mouse model of late-onset retinal macular degeneration. *PLoS One* 6, e27433.
- Sidjanin, D.J., Lowe, J.K., McElwee, J.L., Milne, B.S., Phippen, T.M., Sargan, D.R., Aguirre, G.D., Acland, G.M., Ostrander, E.A., 2002. Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3. *Hum. Mol. Genet.* 11, 1823–1833.
- Singh, K.K., Dawson, W.W., Krawczak, M., Schmidtke, J., 2007. IMPG1 gene variation in rhesus macular drusen. *Vet. Ophthalmol.* 10, 274–277.
- Sisk, R.A., Berrocal, A.M., Lam, B.L., 2010. Loss of foveal cone photoreceptor outer segments in occult macular dystrophy. *Ophthalmic Surg. Lasers Imaging*, 1–3.
- Small, K.W., 1989. North Carolina macular dystrophy, revisited. *Ophthalmology* 96, 1747–1754.
- Small, K.W., Killian, J., McLean, W.C., 1991. North Carolina's dominant progressive foveal dystrophy: how progressive is it? *Br. J. Ophthalmol.* 75, 401–406.
- Small, K.W., Weber, J.L., Roses, A., Lennon, F., Vance, J.M., Pericak-Vance, M.A., 1992. North Carolina macular dystrophy is assigned to chromosome 6. *Genomics* 13, 681–685.
- Smallwood, P.M., Olveczky, B.P., Williams, G.L., Jacobs, G.H., Reese, B.E., Meister, M., Nathans, J., 2003. Genetically engineered mice with an additional class of cone photoreceptors: implications for the evolution of color vision. *Proc. Natl. Acad. Sci. U. S. A.* 100, 11706–11711.
- Sommer, J.R., Estrada, J.L., Collins, E.B., Bedell, M., Alexander, C.A., Yang, Z., Hughes, G., Mir, B., Gilger, B.C., Grob, S., Wei, X., Piedrahita, J.A., Shaw, P.X., Petters, R.M., Zhang, K., 2011. Production of ELOVL4 transgenic pigs: a large animal model for Stargardt-like macular degeneration. *Br. J. Ophthalmol.* 95, 1749–1754.
- Sparrow, J.R., Vollmer-Snarr, H.R., Zhou, J., Jang, Y.P., Jockusch, S., Itagaki, Y., Nakanishi, K., 2003. A2E-epoxides damage DNA in retinal pigment epithelial cells. Vitamin E and other antioxidants inhibit A2E-epoxide formation. *J. Biol. Chem.* 278, 18207–18213.
- Specht, D., Wu, S.B., Turner, P., Dearden, P., Koentgen, F., Wolfgram, U., Maw, M., Brandstätter, J.H., Tom Dieck, S., 2009. Effects of presynaptic mutations on a postsynaptic Ca_v1 calcium channel colocalized with mGluR6 at mouse photoreceptor ribbon synapses. *Investig. Ophthalmol. Vis. Sci.* 50, 505–515.
- Stargardt, K., 1909. Ueber familiäre, progressive Degeneration in der Makulagegend des Auges. *Graefes Arch. Clin. Exp. Ophthalmol.* 71, 534–549.
- Steinberg, R.H., Fisher, S.K., Anderson, D.H., 1980. Disc morphogenesis in vertebrate photoreceptors. *J. Comp. Neurol.* 190, 501–508.
- Steinfeld, R., Reinhardt, K., Schreiber, K., Hillebrand, M., Kraetzner, R., Bruck, W., Saftig, P., Gartner, J., 2006. Cathepsin D deficiency is associated with a human neurodegenerative disorder. *Am. J. Hum. Genet.* 78, 988–998.
- Stiebel-Kalish, H., Reich, E., Rainy, N., Vatine, G., Nisgav, Y., Tovar, A., Gonthilf, Y., Bach, M., 2012. Gucy2f zebrafish knockdown—a model for Gucy2d-related leber congenital amaurosis. *Eur. J. Hum. Genet.* 20, 884–889.
- Stockman, A., Henning, G.B., Michaelides, M., Moore, A.T., Webster, A.R., Cammack, J., Ripamonti, C., 2014. Cone dystrophy with “supernormal” rod ERG: psychophysical testing shows comparable rod and cone temporal sensitivity losses with no gain in rod function. *Investig. Ophthalmol. Vis. Sci.* 55, 832–840.
- Stone, E.M., 2007. Leber congenital amaurosis — a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. *Am. J. Ophthalmol.* 144, 791–811.
- Stone, E.M., Lotery, A.J., Munier, F.L., Heon, E., Piguet, B., Guymer, R.H., Vandenburgh, K., Cousin, P., Nishimura, D., Swiderski, R.E., Silvestri, G., Mackey, D.A., Hageman, G.S., Bird, A.C., Sheffield, V.C., Schorderet, D.F., 1999. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyme honeycomb retinal dystrophy. *Nat. Genet.* 22, 199–202.
- Sun, H., Molday, R.S., Nathans, J., 1999. Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease. *J. Biol. Chem.* 274, 8269–8281.
- Sun, H., Nathans, J., 1997. Stargardt's ABCR is localized to the disc membrane of retinal rod outer segments. *Nat. Genet.* 17, 15–16.
- Sun, X., Pawlyk, B., Xu, X., Liu, X., Bulgakov, O.V., Adamian, M., Sandberg, M.A., Khani, S.C., Tan, M.H., Smith, A.J., Ali, R.R., Li, T., 2010. Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIP1 mutations. *Gene Ther.* 17, 117–131.
- Sundaram, V., Wilde, C., Aboshiha, J., Cowing, J., Han, C., Langlo, C.S., Chana, R., Davidson, A.E., Sergouniotis, P.I., Bainbridge, J.W., Ali, R.R., Dubra, A., Rubin, G., Webster, A.R., Moore, A.T., Nardini, M., Carroll, J., Michaelides, M., 2014. Retinal structure and function in achromatopsia: implications for gene therapy. *Ophthalmology* 121, 234–245.
- Sundin, O.H., Yang, J.M., Li, Y., Zhu, D., Hurd, J.N., Mitchell, T.N., Silva, E.D., Maumenee, I.H., 2000. Genetic basis of total colourblindness among the Pingelapese islanders. *Nat. Genet.* 25, 289–293.
- Tan, M.H., Smith, A.J., Pawlyk, B., Xu, X., Liu, X., Bainbridge, J.B., Basche, M., McIntosh, J., Tran, H.V., Nathwani, A., Li, T., Ali, R.R., 2009. Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIP1: effective rescue of mouse models of partial and complete Aip1 deficiency using AAV2/2 and AAV2/8 vectors. *Hum. Mol. Genet.* 18, 2099–2114.
- Thanos, S., Mey, J., 2001. Development of the visual system of the chick. II. Mechanisms of axonal guidance. *Brain Res. Brain Res. Rev.* 35, 205–245.
- Thiadens, A.A., den Hollander, A.I., Roosing, S., Nabuurs, S.B., Zekveld-Vroon, R.C., Collin, R.W.J., De, B.E., Koenekoop, R.K., van Schooneveld, M.J., Strom, T.M., van Lith-Verhoeven, J.J., Lotery, A.J., van Moll-Ramirez, N., Leroy, B.P., van den Born, L.L., Hoyng, C.B., Cremers, F.P., Klaver, C.C., 2009a. Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders. *Am. J. Hum. Genet.* 85, 240–247.
- Thiadens, A.A., Hoyng, C.B., Polling, J.R., Bernaerts-Biskop, R., van den Born, L.L., Klaver, C.C., 2013. Accuracy of four commonly used color vision tests in the identification of cone disorders. *Ophthalmic Epidemiol.* 20, 114–121.
- Thiadens, A.A., Phan, T.M., Zekveld-Vroon, R.C., Leroy, B.P., van den Born, L.L., Hoyng, C.B., Klaver, C.C., Roosing, S., Pott, J.W., van Schooneveld, M.J., van Moll-Ramirez, N., van Genderen, M.M., Boon, C.J., den Hollander, A.I., Bergen, A.A., De, B.E., Cremers, F.P., Lotery, A.J., 2012a. Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy. *Ophthalmology* 119, 819–826.
- Thiadens, A.A., Slingerland, N.W., Florijn, R.J., Visser, G.H., Riemslag, F.C., Klaver, C.C., 2012b. Cone-rod dystrophy can be a manifestation of Danon disease. *Graefes Arch. Clin. Exp. Ophthalmol.* 250, 769–774.
- Thiadens, A.A., Slingerland, N.W., Roosing, S., van Schooneveld, M.J., van Lith-Verhoeven, J.J., van Moll-Ramirez, N., van den Born, L.L., Hoyng, C.B., Cremers, F.P., Klaver, C.C., 2009b. Genetic etiology and clinical consequences of complete and incomplete achromatopsia. *Ophthalmology* 116, 1984, 1989 e1981.
- Thompson, D.A., Khan, N.W., Othman, M.I., Chang, B., Jia, L., Grahek, G., Wu, Z., Hiriyanna, S., Nellisery, J., Li, T., Khanna, H., Colosi, P., Swaroop, A., Heckenlively, J.R., 2012. Rd9 is a naturally occurring mouse model of a common form of retinitis pigmentosa caused by mutations in RPGR-ORF15. *PLoS One* 7, e35865.
- Thoreson, W.B., Witkovsky, P., 1999. Glutamate receptors and circuits in the vertebrate retina. *Prog. Retin. Eye Res.* 18, 765–810.
- Tian, D., Lev, S., 2002. Cellular and developmental distribution of human homologues of the Drosophila rdgB protein in the rat retina. *Investig. Ophthalmol. Vis. Sci.* 43, 1946–1953.
- Toyofuku, T., Nojima, S., Ishikawa, T., Takamatsu, H., Tsujimura, T., Uemura, A., Matsuda, J., Seki, T., Kumanogoh, A., 2012. Endosomal sorting by Semaphorin 4A in retinal pigment epithelium supports photoreceptor survival. *Genes Dev.* 26, 816–829.
- Travis, G.H., Golczak, M., Moise, A.R., Palczewski, K., 2007. Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. *Annu. Rev. Pharmacol. Toxicol.* 47, 469–512.
- Travis, G.H., Sutcliffe, J.G., Bok, D., 1991. The retinal degeneration slow (rds) gene product is a photoreceptor disc membrane-associated glycoprotein. *Neuron* 6, 61–70.
- Tucker, B.A., Mullins, R.F., Streb, L.M., Anfinson, K., Eyestone, M.E., Kaalberg, E., Riker, M.J., Drack, A.V., Braun, T.A., Stone, E.M., 2013. Patient-specific iPSC-derived photoreceptor precursor cells as a means to investigate retinitis pigmentosa. *Elife* 2, e00824.
- Tuson, M., Garanto, A., Gonzalez-Duarte, R., Marfany, G., 2009. Overexpression of CERKL, a gene responsible for retinitis pigmentosa in humans, protects cells from apoptosis induced by oxidative stress. *Mol. Vis.* 15, 168–180.
- Ueyama, H., Muraki-Oda, S., Yamada, S., Tanabe, S., Yamashita, T., Shichida, Y., Ogita, H., 2012. Unique haplotype in exon 3 of cone opsin mRNA affects splicing

- of its precursor, leading to congenital color vision defect. *Biochem. Biophys. Res. Commun.* 424, 152–157.
- van Dorp, D.B., Wright, A.F., Carothers, A.D., Bleeker-Wagemakers, E.M., 1992. A family with RP3 type of X-linked retinitis pigmentosa: an association with ciliary abnormalities. *Hum. Genet.* 88, 331–334.
- van Lith-Verhoeven, J.J., Hoyng, C.B., van den Helm, B., Deutman, A.F., Brink, H.M., Kemperman, M.H., de Jong, W.H., Kremer, H., Cremers, F.P., 2004. The benign concentric annular macular dystrophy locus maps to 6p12.3-q16. *Investig. Ophthalmol. Vis. Sci.* 45, 30–35.
- van Lith, G.H.M., 1973. General cone dysfunction without achromatopsia. In: Pearlman, J.T. (Ed.), 10th ISCEG Symposium, Doc Ophthalmol Proc Ser, pp. 175–180.
- Vasireddy, V., Jablonski, M.M., Mandal, M.N., Raz-Prag, D., Wang, X.F., Nizol, L., Iannaccone, A., Musch, D.C., Bush, R.A., Salem Jr, N., Sieving, P.A., Ayyagari, R., 2006. Elov14 5-bp-deletion knock-in mice develop progressive photoreceptor degeneration. *Investig. Ophthalmol. Vis. Sci.* 47, 4558–4568.
- Vekslin, S., Ben-Yosef, T., 2010. Spatiotemporal expression pattern of ceramide kinase-like in the mouse retina. *Mol. Vis.* 16, 2539–2549.
- Vesa, J., Hellsten, E., Verkruse, L.A., Camp, L.A., Rapola, J., Santavuori, P., Hofmann, S.L., Peltonen, L., 1995. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. *Nature* 376, 584–587.
- Vincent, A., Wright, T., Billingsley, G., Westall, C., Heon, E., 2011. Oligocone trichromacy is part of the spectrum of CNGA3-related cone system disorders. *Ophthalmic Genet.* 32, 107–113.
- Wabbers, B., Preising, M.N., Kretschmann, U., Demmler, A., Lorenz, B., 2006. Genotype-phenotype correlation and longitudinal course in ten families with Best vitelliform macular dystrophy. *Graefes Arch. Clin. Exp. Ophthalmol.* 244, 1453–1466.
- Wada, Y., Abe, T., Itabashi, T., Sato, H., Kawamura, M., Tamai, M., 2003. Autosomal dominant macular degeneration associated with 208delG mutation in the FSCN2 gene. *Arch. Ophthalmol.* 121, 1613–1620.
- Walz, A., Feinstein, P., Khan, M., Mombaerts, P., 2007. Axonal wiring of guanylate cyclase-D-expressing olfactory neurons is dependent on neuropilin 2 and semaphorin 3F. *Development* 134, 4063–4072.
- Wang, Q.L., Chen, S., Esumi, N., Swain, P.K., Haines, H.S., Peng, G., Melia, B.M., McIntosh, I., Heckenlively, J.R., Jacobson, S.G., Stone, E.M., Swaroop, A., Zack, D.J., 2004. QRX, a novel homeobox gene, modulates photoreceptor gene expression. *Hum. Mol. Genet.* 13, 1025–1040.
- Wätzlich, D., Vetter, I., Gotthardt, K., Miertzschke, M., Chen, Y.X., Wittinghofer, A., Ismail, S., 2013. The interplay between RPRG, PDEdelta and Arl2/3 regulate the ciliary targeting of farnesylated cargo. *EMBO Rep.* 14, 465–472.
- Weber, B.H., Lin, B., White, K., Kohler, K., Soboleva, G., Herterich, S., Seeliger, M.W., Jaissle, G.B., Grimm, C., Reme, C., Wenzel, A., Asan, E., Schrewe, H., 2002. A mouse model for Sorsby fundus dystrophy. *Investig. Ophthalmol. Vis. Sci.* 43, 2732–2740.
- Weber, B.H., Vogt, G., Pruett, R.C., Stohr, H., Felbor, U., 1994. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. *Nat. Genet.* 8, 352–356.
- Weng, J., Mata, N.L., Azarian, S.M., Tzekov, R.T., Birch, D.G., Travis, G.H., 1999. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. *Cell* 98, 13–23.
- Weskamp, G., Cai, H., Brodie, T.A., Higashiyama, S., Manova, K., Ludwig, T., Blobel, C.P., 2002. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. *Mol. Cell. Biol.* 22, 1537–1544.
- West, E.L., Pearson, R.A., Tschernutter, M., Sowden, J.C., MacLaren, R.E., Ali, R.R., 2008. Pharmacological disruption of the outer limiting membrane leads to increased retinal integration of transplanted photoreceptor precursors. *Exp. Eye Res.* 86, 601–611.
- Westeneng-van Haften, S.C., Boon, C.J., Cremers, F.P., Hoefsloot, L.H., den Hollander, A.I., Hoyng, C.B., 2012. Clinical and genetic characteristics of late-onset Stargardt's disease. *Ophthalmology* 119, 1199–1210.
- Wickham, L., Chen, F.K., Lewis, G.P., Uppal, G.S., Neveu, M.M., Wright, G.A., Robson, A.G., Webster, A.R., Grierson, I., Hiscott, P., Coffey, P.J., Holder, G.E., Fisher, S.K., Da Cruz, L., 2009. Clinicopathological case series of four patients with inherited macular disease. *Investig. Ophthalmol. Vis. Sci.* 50, 3553–3561.
- Wissinger, B., Dangel, S., Jagle, H., Hansen, L., Baumann, B., Rudolph, G., Wolf, C., Bonin, M., Koeppen, K., Ladewig, T., Kohl, S., Zrenner, E., Rosenberg, T., 2008. Cone dystrophy with supernormal rod response is strictly associated with mutations in KCNV2. *Investig. Ophthalmol. Vis. Sci.* 49, 751–757.
- Wissinger, B., Gamer, D., Jagle, H., Giorda, R., Marx, T., Mayer, S., Tippmann, S., Broghammer, M., Jurkies, B., Rosenberg, T., Jacobson, S.G., Sener, E.C., Tatlipinar, S., Hoyng, C.B., Castellani, C., Bitoun, P., Andreasson, S., Rudolph, G., Kellner, U., Lorenz, B., Wolff, G., Verellen-Dumoulin, C., Schwartz, M., Cremers, F.P., Apfelstedt-Sylla, E., Zrenner, E., Salati, R., Sharpe, L.T., Kohl, S., 2001. CNGA3 mutations in hereditary cone photoreceptor disorders. *Am. J. Hum. Genet.* 69, 722–737.
- Won, J., Gifford, E., Smith, R.S., Yi, H., Ferreira, P.A., Hicks, W.L., Li, T., Naggert, J.K., Nishina, P.M., 2009. RPRG1 is essential for normal rod photoreceptor outer segment elaboration and morphogenesis. *Hum. Mol. Genet.* 18, 4329–4339.
- Won, J., Shi, L.Y., Hicks, W., Wang, J., Hurd, R., Naggert, J.K., Chang, B., Nishina, P.M., 2011. Mouse model resources for vision research. *J. Ophthalmol.* 2011, 391384.
- Wright, K.J., Baye, L.M., Olivier-Mason, A., Mukhopadhyay, S., Sang, L., Kwong, M., Wang, W., Pretorius, P.R., Sheffield, V.C., Sengupta, P., Slusarski, D.C., Jackson, P.K., 2011. An ARL3-UNC119-RP2 GTPase cycle targets myristoylated NPHP3 to the primary cilium. *Genes Dev.* 25, 2347–2360.
- Wu, H., Cowing, J.A., Michaelides, M., Wilkie, S.E., Jeffery, G., Jenkins, S.A., Mester, V., Bird, A.C., Robson, A.G., Holder, G.E., Moore, A.T., Hunt, D.M., Webster, A.R., 2006. Mutations in the gene KCNV2 encoding a voltage-gated potassium channel subunit cause "cone dystrophy with supernormal rod electroretinogram" in humans. *Am. J. Hum. Genet.* 79, 574–579.
- Wycisk, K.A., Zeitz, C., Feil, S., Wittmer, M., Forster, U., Neidhardt, J., Wissinger, B., Zrenner, E., Wilke, R., Kohl, S., Berger, W., 2006. Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy. *Am. J. Hum. Genet.* 79, 973–977.
- Yamashita, T., Liu, J., Gao, J., LeNoue, S., Wang, C., Kaminoh, J., Bowne, S.J., Sullivan, L.S., Daiger, S.P., Zhang, K., Fitzgerald, M.E., Kefalov, V.J., Zuo, J., 2009. Essential and synergistic roles of RP1 and RP1L1 in rod photoreceptor axonem and retinitis pigmentosa. *J. Neurosci.* 29, 9748–9760.
- Yang, Z., Kitsos, G., Tong, Z., Payne, M., Gorezis, S., Psilas, K., Grigoriadou, M., Zhao, Y., Kamaya, S., Aperis, G., Petersen, M.B., Zhang, K., 2006. A novel locus on 19q13 associated with autosomal-dominant macular dystrophy in a large Greek family. *J. Med. Genet.* 43, e57.
- Yang, Z., Tong, Z., Chorich, L.J., Pearson, E., Yang, X., Moore, A., Hunt, D.M., Zhang, K., 2008. Clinical characterization and genetic mapping of North Carolina macular dystrophy. *Vis. Res.* 48, 470–477.
- Yatsenko, A.N., Shroyer, N.F., Lewis, R.A., Lupski, J.R., 2001. Late-onset Stargardt disease is associated with missense mutations that map outside known functional regions of ABCR (ABCA4). *Hum. Genet.* 108, 346–355.
- Yeh, C.Y., Goldstein, O., Kukekova, A.V., Holley, D., Knollinger, A.M., Huson, H.J., Pearce-Kelling, S.E., Acland, G.M., Komáromy, A.M., 2013. Genomic deletion of CNGB3 is identical by descent in multiple canine breeds and causes achromatopsia. *BMC Genet.* 14, 27.
- Yokokura, S., Wada, Y., Nakai, S., Sato, H., Yao, R., Yamanaka, H., Ito, S., Sagara, Y., Takahashi, M., Nakamura, Y., Tamai, M., Noda, T., 2005. Targeted disruption of FSCN2 gene induces retinopathy in mice. *Investig. Ophthalmol. Vis. Sci.* 46, 2905–2915.
- Young, R.W., 1967. The renewal of photoreceptor cell outer segments. *J. Cell Biol.* 33, 61–72.
- Yzer, S., Barbazetto, I., Allikmets, R., van Schooneveld, M.J., Bergen, A., Tsang, S.H., Jacobson, S.G., Yannuzzi, L.A., 2013. Expanded clinical spectrum of enhanced S-cone syndrome. *JAMA Ophthalmol.* 131, 1324–1330.
- Zachigna, S., Oh, H., Wilsch-Brauninger, M., Missol-Kolka, E., Jaszi, J., Jansen, S., Tanimoto, N., Tonagel, F., Seeliger, M., Huttner, W.B., Corbeil, D., Dewerrchin, M., Vinckier, S., Moons, L., Carmeliet, P., 2009. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. *J. Neurosci.* 29, 2297–2308.
- Zambrowicz, B.P., Abuin, A., Ramirez-Solis, R., Richter, L.J., Piggott, J., BeltrandelRio, H., Buxton, E.C., Edwards, J., Finch, R.A., Friddle, C.J., Gupta, A., Hansen, G., Hu, Y., Huang, W., Jaing, C., Key Jr, B.W., Kipp, P., Kohlhauff, B., Ma, Z.Q., Markesich, D., Payne, R., Potter, D.G., Qian, N., Shaw, J., Schrick, J., Shi, Z.Z., Sparks, M.J., Van Slightenhorst, I., Vogel, P., Walke, W., Xu, N., Zhu, Q., Person, C., Sands, A.T., 2003. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. *Proc. Natl. Acad. Sci. U. S. A.* 100, 14109–14114.
- Zangerl, B., Wickstrom, K., Slavik, J., Lindauer, S.J., Ahonen, S., Schelling, C., Lohi, H., Guzewicz, K.E., Aguirre, G.D., 2010. Assessment of canine BEST1 variations identifies new mutations and establishes an independent bestrophinopathy model (cmr3). *Mol. Vis.* 16, 2791–2804.
- Zeitz, C., Jacobson, S.G., Hamel, C.P., Bujakowska, K., Neuille, M., Orhan, E., Zanlonghi, X., Lancelot, M.E., Michiels, C., Schwartz, S.B., Bocquet, B., Consortium, C.S.N.B., Antonio, A., Audier, C., Letexier, M., Saraiva, J.P., Luu, T.D., Sennlaub, F., Nguyen, H., Poch, O., Dollfus, H., Lecompte, O., Kohl, S., Sahel, J.A., Bhattacharya, S.S., Audo, I., 2013. Whole-exome sequencing identifies LRIT3 mutations as a cause of autosomal-recessive complete congenital stationary night blindness. *Am. J. Hum. Genet.* 92, 67–75.
- Zelinger, L., Wissinger, B., Eli, D., Kohl, S., Sharon, D., Banin, E., 2013. Cone dystrophy with supernormal rod response: novel KCNV2 mutations in an underdiagnosed phenotype. *Ophthalmology* 120, 2338–2343.
- Zhang, H., Constantine, R., Vorobiev, S., Chen, Y., Seetharaman, J., Huang, Y.J., Xiao, R., Montelione, G.T., Gerstner, C.D., Davis, M.W., Inana, G., Whitby, F.G., Jorgensen, E.M., Hill, C.P., Tong, L., Baehr, W., 2011. UNC119 is required for G protein trafficking in sensory neurons. *Nat. Neurosci.* 14, 874–880.
- Zhang, K., Garibaldi, D.C., Li, Y., Green, W.R., Zack, D.J., 2002a. Butterfly-shaped pattern dystrophy: a genetic, clinical, and histopathological report. *Arch. Ophthalmol.* 120, 485–490.
- Zhang, Q., Acland, G.M., Wu, W.X., Johnson, J.L., Pearce-Kelling, S., Tulloch, B., Vervoort, R., Wright, A.F., Aguirre, G.D., 2002b. Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. *Hum. Mol. Genet.* 11, 993–1003.
- Zhang, Y., Stanton, J.B., Wu, J., Yu, K., Hartzell, H.C., Peachey, N.S., Marmorstein, L.Y., Marmorstein, A.D., 2010. Suppression of Ca²⁺ signaling in a mouse model of best disease. *Hum. Mol. Genet.* 19, 1108–1118.
- Zhao, Y., Hong, D.H., Pawlyk, B., Yue, G., Adamian, M., Grynberg, M., Godzik, A., Li, T., 2003. The retinitis pigmentosa GTPase regulator (RPGR)-interacting protein: subserving RPGR function and participating in disk morphogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 100, 3965–3970.

- Zheng, L., Yan, Y., An, J., Zhang, L., Liu, W., Xia, F., Zhang, Z., 2012. Retinal horizontal cells reduced in a rat model of congenital stationary night blindness. *Neurosci. Lett.* 521, 26–30.
- Zhu, L., Gibson, P., Curre, D.S., Tong, Y., Richardson, R.J., Bayazitov, I.T., Poppleton, H., Zakharenko, S., Ellison, D.W., Gilbertson, R.J., 2009. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. *Nature* 457, 603–607.
- Zito, I., Downes, S.M., Patel, R.J., Cheetham, M.E., Ebenezer, N.D., Jenkins, S.A., Bhattacharya, S.S., Webster, A.R., Holder, G.E., Bird, A.C., Bamiou, D.E., Hardcastle, A.J., 2003. RPGR mutation associated with retinitis pigmentosa, impaired hearing, and sinorespiratory infections. *J. Med. Genet.* 40, 609–615.